Faculty Collaboration Database

1. Karuturi M, Shah N, Frank D, Fasan O, Reshef R, Ahya VN, Bromberg M, Faust T, Goral S, Schuster SJ, Stadtmauer EA, Tsai DE. Plasmacytic post-transplant lymphoproliferative disorder: a case series of nine patients. Transpl Int. 2013 Jun;26(6):616-22.

2. Shah NN, Harrison N, Stonecypher M, Frank D, Amorosa V, Svoboda J. Extracavitary primary effusion lymphoma initially presenting with hemophagocytic lymphohistocytosis. Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):e157-60.

3. Nagle SJ, Chong EA, Chekol S, Shah NN, Nasta SD, Glatstein E, Plastaras JP, Torigian DA, Schuster SJ, Svoboda J. The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma. Cancer Med. 2015 Jan;4(1):7-15. PMCID: PMC4312112

4. Shah NN, Kucharczuk CR, Mitra N, Hirsh R, Svoboda J, Porter D, Loren A, Frey N, Schapira MM. Implementation of an Advanced Practice Provider Service on an Allogeneic Stem Cell Transplant Unit: Impact on Patient Outcomes. Biol Blood Marrow Transplant. 2015 Sep;21(9):1692-8.

5. Shah NN, Stonecypher M, Gopal P, Luger S, Bagg A, Perl A. Acute promyelocytic leukemia presenting as a paraspinal mass. J Community Support Oncol. 2016 Mar;14(3):126-9.

6. Shah, N.N., N. Mitra, J. Brikman, S. Nasta, D. Landsburg, A. Mato, D. Vogl, N. Frey, S.J. Schuster, and J. Svoboda, Split-dose R-CHOP: A new approach to administer cytotoxic chemo-immunotherapy to elderly patients with DLBCL. Journal of Community and Supportive Oncology, 2016. 14(11): p. 450-456.

7. Shah NN, Casella E, Capozzi D, McGettigan S, Gangadhar TC, Schuchter L, Myers JS. Improving the Safety of Oral Chemotherapy at an Academic Medical Center. J Oncol Pract. 2016 Jan;12(1):e71-6. PMCID: PMC4960462

8. Epperla N, Harrington AM, Hemauer K, Shah NN. Extracavitary primary effusion lymphoma associated with hemophagocytic lymphohistiocytosis. Am J Hematol. 2016 Nov;91(11):1161-1164.

9. Dhakal B, Fenske TS, Ramalingam S, Shuff J, Epperla N, Hosking P, Rein L, Banerjee A, Hari P, D'Souza A, Shah N, Siker M, Griepentrog GJ, Harris GJ, Wells TS, Erickson BA, Hamadani M. Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. Clin Lymphoma Myeloma Leuk. 2017 May;17(5):305-311.e2.

10. Jerkins JH, Hamadani M, Zook F, Epperla N, Shaw BE, Saber W, Rizzo JD, Pasquini M, Chhabra S, Drobyski WR, Hari PN, Shah NN. Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. Am J Hematol. 2017 Oct;92(10):E610-E611.

11. Thompson J, Yin Z, D'Souza A, Fenske T, Hamadani M, Hari P, Rizzo JD, Pasquini M, Saber W, Shah N, Shaw BE, Shahir K, Banerjee A, Drobyski WR. Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome. Biol Blood Marrow Transplant. 2017 Nov;23(11):1955-1960.

12. Voshtina, E., H. Olteanu, B. Graner, and N.N. Shah, Hodgkin Lymphoma Presenting with Dural Involvement. Annals of Hematology & Oncology, 2017. 4(12): p. 1-3.

13. Bhella S, Majhail NS, Betcher J, Costa LJ, Daly A, Dandoy CE, DeFilipp Z, Doan V, Gulbis A, Hicks L, Juckett M, Khera N, Krishnan A, Selby G, Shah NN, Stricherz M, Viswabandya A, Bredeson C, Seftel MD. Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group's List of 5 Tests and Treatments to Question in Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2018 May;24(5):909-913.

14. Zhu F, Shah N, Xu H, Schneider D, Orentas R, Dropulic B, Hari P, Keever-Taylor CA. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. Cytotherapy. 2018 Mar;20(3):394-406.

15. Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, Vose J, Obiozor C, Faruqi F, Kovach AE, Costa LJ, Xavier AC, Okal R, Kanate AS, Ghosh N, Kharfan-Dabaja MA, Strelec L, Hamadani M, Fenske TS, Calzada O, Cohen JB, Chavez J, Svoboda J. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol. 2018 Feb;180(4):534-544.

16. Drobyski WR, Szabo A, Zhu F, Keever-Taylor C, Hebert KM, Dunn R, Yim S, Johnson B, D'Souza A, Eapen M, Fenske TS, Hari P, Hamadani M, Horowitz MM, Rizzo JD, Saber W, Shah N, Shaw B, Pasquini M. Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-<i>versus</i>-host disease: low incidence of lower gastrointestinal tract disease. Haematologica. 2018 Apr;103(4):717-727. PMCID: PMC5865423

17. Epperla N, Ahn KW, Armand P, Jaglowski S, Ahmed S, Kenkre VP, Savani B, Jagasia M, Shah NN, Fenske TS, Sureda A, Smith SM, Hamadani M. Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. Biol Blood Marrow Transplant. 2018 Jan;24(1):78-85. PMCID: PMC5743624

18. Nagle SJ, Shah NN, Ganetsky A, Landsburg DJ, Nasta SD, Mato A, Schuster SJ, Reshef R, Tsai DE, Svoboda J. Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNS. Int J Hematol Oncol. 2017 Dec;6(4):113-121. PMCID: PMC6171986

19. Shah NN, Fenske TS, Hamadani M, Svoboda J. What is the standard of care for primary mediastinal B cell lymphoma; R-CHOP or DA-EPOCH-R? - Response to Melani et al. Br J Haematol. 2019 Mar;184(5):838-840.

20. Sinkoff J, Olteanu H, Peterson JF, Shah NN. Leukemic phase and CSF involvement of diffuse large B-cell lymphoma with a complex karyotype including a <i>TP53</i> deletion. Clin Case Rep. 2018 Jan;6(1):235-237. PMCID: PMC5771872

21. Singavi AK, Shah NN. Graft-versus-host disease-associated hepatic portal venous gas. Br J Haematol. 2018 Apr;181(1):9.

22. Smith SM, Godfrey J, Ahn KW, DiGilio A, Ahmed S, Agrawal V, Bachanova V, Bacher U, Bashey A, Bolaños-Meade J, Cairo M, Chen A, Chhabra S, Copelan E, Dahi PB, Aljurf M, Farooq U, Ganguly S, Hertzberg M, Holmberg L, Inwards D, Kanate AS, Karmali R, Kenkre VP, Kharfan-Dabaja MA, Klein A, Lazarus HM, Mei M, Mussetti A, Nishihori T, Ramakrishnan Geethakumari P, Saad A, Savani BN, Schouten HC, Shah N, Urbano-Ispizua A, Vij R, Vose J, Sureda A, Hamadani M. Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. Cancer. 2018 Jun 15;124(12):2541-2551. PMCID: PMC5990449

23. Dhakal B, D'Souza A, Lakshman A, Hamadani M, Chhabra S, Thompson R, Shah N, Pasquini M, Hari P. Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2018 Aug;24(8):1610-1614.

24. Shah NN, Ahn KW, Litovich C, Fenske TS, Ahmed S, Battiwalla M, Bejanyan N, Dahi PB, Bolaños-Meade J, Chen AI, Ciurea SO, Bachanova V, DeFilipp Z, Epperla N, Farhadfar N, Herrera AF, Haverkos BM, Holmberg L, Hossain NM, Kharfan-Dabaja MA, Kenkre VP, Lazarus HM, Murthy HS, Nishihori T, Rezvani AR, D'Souza A, Savani BN, Ulrickson ML, Waller EK, Sureda A, Smith SM, Hamadani M. Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. Blood Adv. 2018 Apr 24;2(8):933-940. PMCID: PMC5916010

25. Knight JM, Kerswill SA, Hari P, Cole SW, Logan BR, D'Souza A, Shah NN, Horowitz MM, Stolley MR, Sloan EK, Giles KE, Costanzo ES, Hamadani M, Chhabra S, Dhakal B, Rizzo JD. Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation. BMC Cancer. 2018 May 24;18(1):593. PMCID: PMC5968588

26. Raj RV, Hamadani M, Szabo A, Pasquini MC, Shah NN, Drobyski WR, Shaw BE, Saber W, Rizzo JD, Jerkins J, Fenske TS, D'Souza A, Dhakal B, Zhang C, Konings S, Hari PN, Chhabra S. Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. Biol Blood Marrow Transplant. 2018 Aug;24(8):1664-1670.

27. Badar T, Hari P, Chhabra S, Dhakal B, Drobyski WR, Fenske TS, Hamadani M, Pasquini M, Saber W, Shah NN, Shaw BE, D'Souza A. Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. Bone Marrow Transplant. 2018 Sep;53(9):1210-1213.

28. Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, Hill BT, Lamanna N, Lansigan F, Jacobs R, Shadman M, Skarbnik AP, Pu JJ, Barr PM, Sehgal AR, Cheson BD, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Goy A, Winter AM, Garcia C, Kennard K, Isaac K, Dorsey C, Gashonia LM, Singavi AK, Roeker LE, Zelenetz A, Williams A, Howlett C, Weissbrot H, Ali N, Khajavian S, Sitlinger A, Tranchito E, Rhodes J, Felsenfeld J, Bailey N, Patel B, Burns TF, Yacur M, Malhotra M, Svoboda J, Furman RR, Nabhan C. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. 2018 Sep;103(9):1511-1517. PMCID: PMC6119152

29. Mato AR, Roeker LE, Allan JN, Pagel JM, Brander DM, Hill BT, Cheson BD, Furman RR, Lamanna N, Tam CS, Handunnetti S, Jacobs R, Lansigan F, Bhavsar E, Barr PM, Shadman M, Skarbnik AP, Goy A, Beach DF, Svoboda J, Pu JJ, Sehgal AR, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Rhodes J, Ujjani CS, Nabhan C. Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. Am J Hematol. 2018 Nov;93(11):1394-1401. PMCID: PMC7552812

30. Voshtina E, Szabo A, Hamadani M, Fenske TS, D'Souza A, Chhabra S, Saber W, Drobyski WR, Hari P, Shah NN. Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies. Biol Blood Marrow Transplant. 2019 Jan;25(1):e33-e38.

31. Shah NN, Singavi AK, Harrington A. Daratumumab in Primary Effusion Lymphoma. N Engl J Med. 2018 Aug 16;379(7):689-690.

32. Sahebi F, Garderet L, Kanate AS, Eikema DJ, Knelange NS, Alvelo OFD, Koc Y, Blaise D, Bashir Q, Moraleda JM, Dreger P, Sanchez JF, Ciurea S, Schouten H, Shah NN, Verbeek M, Rösler W, Diez-Martin JL, Schoenland S, D'Souza A, Kröger N, Hari P. Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report. Biol Blood Marrow Transplant. 2019 Feb;25(2):335-342. PMCID: PMC6339830

33. Shah NN, Nagle SJ, Torigian DA, Farwell MD, Hwang WT, Frey N, Nasta SD, Landsburg D, Mato A, June CH, Schuster SJ, Porter DL, Svoboda J. Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas. Cytotherapy. 2018 Dec;20(12):1415-1418.

34. Fløisand Y, Lazarevic VL, Maertens J, Mattsson J, Shah NN, Zachée P, Taylor A, Akbari M, Quadri S, Parfionovas A, Chen YB. Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review. Biol Blood Marrow Transplant. 2019 Apr;25(4):720-727.

35. Chhabra S, Ahn KW, Hu ZH, Jain S, Assal A, Cerny J, Copelan EA, Daly A, DeFilipp Z, Gadalla SM, Gale RP, Ganguly S, Hamilton BK, Hildebrandt GC, Hsu JW, Inamoto Y, Kanate AS, Khoury HJ, Lazarus HM, Litzow MR, Nathan S, Olsson RF, Pawarode A, Ringden O, Rowe JM, Saad A, Savani BN, Schouten HC, Seo S, Shah NN, Solh M, Stuart RK, Ustun C, Woolfrey AE, Yared JA, Alyea EP, Kalaycio ME, Popat U, Sobecks RM, Saber W. Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. Blood Adv. 2018 Nov 13;2(21):2922-2936. PMCID: PMC6234373

36. Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B, D'Souza A, Drobyski WR, Rizzo JD, Runaas L, Shah NN, Shaw B, Saber W, Fenske T, Hamadani M. Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. Biol Blood Marrow Transplant. 2019 Apr;25(4):827-833.

37. Bair SM, Strelec LE, Feldman TA, Ahmed G, Armand P, Shah NN, Singavi AN, Reddy N, Khan N, Andreadis C, Vu K, Huntington SF, Giri S, Ujjani C, Howlett C, Faheem M, Youngman MR, Nasta SD, Landsburg DJ, Schuster SJ, Svoboda J. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis. Oncologist. 2019 Jul;24(7):955-962. PMCID: PMC6656463

38. Johnson BH, Taylor A, Kim G, Drahos J, Yang J, Akbari M, Shah NN. Clinical Outcomes and Healthcare Resource Utilization for Gastrointestinal Acute Graft-versus-Host Disease after Allogeneic Transplantation for Hematologic Malignancy: A Retrospective US Administrative Claims Database Analysis. Biol Blood Marrow Transplant. 2019 Apr;25(4):834-841.

39. Epperla N, Ahn KW, Litovich C, Ahmed S, Battiwalla M, Cohen JB, Dahi P, Farhadfar N, Farooq U, Freytes CO, Ghosh N, Haverkos B, Herrera A, Hertzberg M, Hildebrandt G, Inwards D, Kharfan-Dabaja MA, Khimani F, Lazarus H, Lazaryan A, Lekakis L, Murthy H, Nathan S, Nishihori T, Pawarode A, Prestidge T, Ramakrishnan P, Rezvani AR, Romee R, Shah NN, Sureda A, Fenske TS, Hamadani M. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. J Hematol Oncol. 2019 Jan 10;12(1):6. PMCID: PMC6329157

40. Levin A, Shah NN. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas. Am J Hematol. 2019 May;94(S1):S18-S23.

41. Shah NN, Maatman T, Hari P, Johnson B. Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies. Front Oncol. 2019;9:146. PMCID: PMC6423158

42. Shah NN, Szabo A, Saba R, Strelec L, Kodali D, Vaughn JL, Esan O, Yang DT, Mato AR, Kanate AS, Olteanu H, Hamadani M, Fenske TS, Kenkre VP, Svoboda J, Cashen AF, Epperla N. Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):95-102.

43. Epperla N, Badar T, Szabo A, Vaughn J, Borson S, Saini NY, Patel RD, Shah NN, Hamadani M, Ahmed S, Cashen AF, Fenske TS. Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. Blood Adv. 2019 Jun 11;3(11):1661-1669. PMCID: PMC6560348

44. Mato AR, Roeker LE, Eyre TA, Nabhan C, Lamanna N, Hill BT, Brander DM, Barr PM, Lansigan F, Cheson BD, Singavi AK, Yazdy MS, Shah NN, Allan JN, Bhavsar EB, Rhodes J, Kennard K, Schuster SJ, Williams AM, Skarbnik AP, Goy AH, Goodfriend JM, Dorsey C, Coombs CC, Tuncer H, Ujjani CS, Jacobs R, Winter AM, Pagel JM, Bailey N, Schuh A, Shadman M, Sitlinger A, Weissbrot H, Muralikrishnan S, Zelenetz A, Kirkwood AA, Fox CP. A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. Blood Adv. 2019 May 28;3(10):1568-1573. PMCID: PMC6538868

45. Dhakal B, Giri S, Levin A, Rein L, Fenske TS, Chhabra S, Shah NN, Szabo A, D'Souza A, Pasquini M, Hari P, Hamadani M. Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals. JAMA Netw Open. 2019 Jul 03;2(7):e196476. PMCID: PMC12124690

46. Abedin S, McKenna E, Chhabra S, Pasquini M, Shah NN, Jerkins J, Baim A, Runaas L, Longo W, Drobyski W, Hari PN, Hamadani M. Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 Aug;25(8):1689-1694.

47. D'Souza A, Hari P, Pasquini M, Braun T, Johnson B, Lundy S, Couriel D, Hamadani M, Magenau J, Dhakal B, Shah NN, Riwes M, Parkin B, Reddy P, Pawarode A. A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant. 2019 Aug;25(8):1492-1497.

48. Kanate AS, Szabo A, Raj RV, Bower K, Grulke R, Shah N, Ross KG, Cumpston A, Craig M, Pasquini MC, Shah N, Hari P, Hamadani M, Chhabra S. Comparison of Graft Acquisition and Early Direct Charges of Haploidentical Related Donor Transplantation versus Umbilical Cord Blood Transplantation. Biol Blood Marrow Transplant. 2019 Jul;25(7):1456-1464.

49. Dhakal B, D'Souza A, Hamadani M, Arce-Lara C, Schroeder K, Chhabra S, Shah NN, Gauger K, Keaton T, Pasquini M, Hari P. Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. Blood Cancer J. 2019 Jul 29;9(8):56. PMCID: PMC6663939

50. Roeker LE, Fox CP, Eyre TA, Brander DM, Allan JN, Schuster SJ, Nabhan C, Hill BT, Shah NN, Lansigan F, Yazdy M, Cheson BD, Lamanna N, Singavi AK, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Tuncer HH, Winter AM, Rhodes J, Dorsey C, Morse H, Kabel C, Pagel JM, Williams AM, Jacobs R, Goy A, Muralikrishnan S, Pearson L, Sitlinger A, Bailey N, Schuh A, Kirkwood AA, Mato AR. Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. Clin Cancer Res. 2019 Jul 15;25(14):4264-4270. PMCID: PMC8020996

51. Guru Murthy GS, Szabo A, Hamadani M, Fenske TS, Shah NN. Contemporary Outcomes for Advanced-Stage Classical Hodgkin Lymphoma in the U.S.: Analysis of Surveillance, Epidemiology, and End Results Database. Oncologist. 2019 Nov;24(11):1488-1495. PMCID: PMC6853108

52. Badar T, Khan MA, Szabo A, Drobyski W, Chhabra S, Dhakal B, Fenske TS, Hamadani M, Hari P, Jerkins JH, Shah NN, Shaw BE, D'Souza A. Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. Amyloid. 2019 Dec;26(4):210-215.

53. Solomon SR, St Martin A, Shah NN, Fatobene G, Al Malki MM, Ballen KK, Bashey A, Bejanyan N, Bolaños Meade J, Brunstein CG, DeFilipp Z, Champlin RE, Fuchs EJ, Hamadani M, Hematti P, Kanakry CG, McGuirk JP, McNiece IK, Ciurea SO, Pasquini MC, Rocha V, Romee R, Patel SS, Vasu S, Waller EK, Wingard JR, Zhang MJ, Eapen M. Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. Blood Adv. 2019 Oct 08;3(19):2836-2844. PMCID: PMC6784523

54. Abid MB, Shah NN, Maatman TC, Hari PN. Gut microbiome and CAR-T therapy. Exp Hematol Oncol. 2019;8:31. PMCID: PMC6862813

55. Chen YB, Shah NN, Renteria AS, Cutler C, Jansson J, Akbari M, Chen C, Quadri S, Parfionovas A, Devine SM. Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2019 Dec 10;3(23):4136-4146. PMCID: PMC6963235

56. Chhabra S, Jerkins JH, Conto JE, Zellner K, Shah NN, Hari PN, Hamadani M. Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease. Leuk Lymphoma. 2020 Apr;61(4):869-874.

57. Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, Mangan JK, Loren AW, Perl AE, Maude SL, Grupp SA, Shah NN, Gilmore J, Lacey SF, Melenhorst JJ, Levine BL, June CH, Porter DL. Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. J Clin Oncol. 2020 Feb 10;38(5):415-422. PMCID: PMC8312030

58. Shah NN, Ahn KW, Litovich C, Sureda A, Kharfan-Dabaja MA, Awan FT, Ganguly S, Gergis U, Inwards D, Karmali R, Lazaryan A, Lekakis L, Munshi P, Nathan S, Saad AA, Solh M, Steinberg A, Vij R, Wood WA, Fenske TS, Smith S, Hamadani M. Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis. Blood Cancer J. 2019 Dec 03;9(12):97. PMCID: PMC6890709

59. Badar T, Epperla N, Szabo A, Borson S, Vaughn J, George G, Saini N, Shah AR, Patel RD, Ahmed S, Shah NN, Cashen AF, Hamadani M, Fenske TS. Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. Blood Adv. 2020 Jan 14;4(1):47-54. PMCID: PMC6960457

60. Knight JM, Rizzo JD, Hari P, Pasquini MC, Giles KE, D'Souza A, Logan BR, Hamadani M, Chhabra S, Dhakal B, Shah N, Sriram D, Horowitz MM, Cole SW. Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial. Blood Adv. 2020 Feb 11;4(3):467-476. PMCID: PMC7013267

61. Badar T, Shah NN. Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Curr Treat Options Oncol. 2020 Feb 05;21(2):16.

62. Chhabra S, Narra RK, Wu R, Szabo A, George G, Michaelis LC, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Pasquini MC, Rizzo RD, Saber W, Shah NN, Shaw BE, Hamadani M, Hari PN. Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. Biol Blood Marrow Transplant. 2020 May;26(5):893-901.

63. Jagasia M, Perales MA, Schroeder MA, Ali H, Shah NN, Chen YB, Fazal S, Dawkins FW, Arbushites MC, Tian C, Connelly-Smith L, Howell MD, Khoury HJ. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020 May 14;135(20):1739-1749. PMCID: PMC7229262

64. Shah NN, Johnson BD, Fenske TS, Raj RV, Hari P. Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome. Blood Adv. 2020 May 26;4(10):2119-2122. PMCID: PMC7252557

65. Shah NN, Jerkins JH, Johnson BD, Hari P. Treatment-Emergent Tumor Lysis Syndrome With PI3Kδ-γ Inhibition After CAR T-Cell Therapy for Chronic Lymphocytic Leukemia. JCO Oncol Pract. 2020 Sep;16(9):613-614.

66. Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Douglas Rizzo J, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M. Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 Oct;26(10):1876-1885. PMCID: PMC7571859

67. Zhou Z, Nath R, Cerny J, Wang HL, Zhang MJ, Abdel-Azim H, Agrawal V, Ahmed G, Al-Homsi AS, Aljurf M, Alkhateeb HB, Assal A, Bacher U, Bajel A, Bashir Q, Battiwalla M, Bhatt VR, Byrne M, Cahn JY, Cairo M, Choe H, Copelan E, Cutler C, Damlaj MB, DeFilipp Z, De Lima M, Diaz MA, Farhadfar N, Foran J, Freytes CO, Gerds AT, Gergis U, Grunwald MR, Gul Z, Hamadani M, Hashmi S, Hertzberg M, Hildebrandt GC, Hossain N, Inamoto Y, Isola L, Jain T, Kamble RT, Khan MW, Kharfan-Dabaja MA, Kebriaei P, Kekre N, Khera N, Lazarus HM, Liesveld JL, Litzow M, Liu H, Marks DI, Martino R, Mathews V, Mishra A, Murthy HS, Nagler A, Nakamura R, Nathan S, Nishihori T, Olin R, Olsson RF, Palmisiano N, Patel SS, Patnaik MM, Pawarode A, Perales MA, Politikos I, Popat U, Rizzieri D, Sandmaier BM, Savani BN, Seo S, Shah NN, Uy GL, Valcárcel D, Verdonck LF, Waller EK, Wang Y, Weisdorf D, Wirk B, Wong E, Yared JA, Saber W. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020 Jul 14;4(13):3180-3190. PMCID: PMC7362362

68. Nazha A, Hu ZH, Wang T, Lindsley RC, Abdel-Azim H, Aljurf M, Bacher U, Bashey A, Cahn JY, Cerny J, Copelan E, DeFilipp Z, Diaz MA, Farhadfar N, Gadalla SM, Gale RP, George B, Gergis U, Grunwald MR, Hamilton B, Hashmi S, Hildebrandt GC, Inamoto Y, Kalaycio M, Kamble RT, Kharfan-Dabaja MA, Lazarus HM, Liesveld JL, Litzow MR, Majhail NS, Murthy HS, Nathan S, Nishihori T, Pawarode A, Rizzieri D, Sabloff M, Savani BN, Schachter L, Schouten HC, Seo S, Shah NN, Solh M, Valcárcel D, Vij R, Warlick E, Wirk B, Wood WA, Yared JA, Alyea E, Popat U, Sobecks RM, Scott BL, Nakamura R, Saber W. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. Biol Blood Marrow Transplant. 2020 Nov;26(11):2139-2146. PMCID: PMC7609542

69. Abid MB, Hamadani M, Szabo A, Hari PN, Graham MB, Frank MO, Collier WS, Abedin S, Jerkins JH, Pasquini MC, Runaas L, Shah NN, Chhabra S. Severity of Cytokine Release Syndrome and Its Association with Infections after T Cell-Replete Haploidentical Related Donor Transplantation. Biol Blood Marrow Transplant. 2020 Sep;26(9):1670-1678.

70. Ujjani C, Mato A, Hill BT, Allan JN, Lansigan F, Jacobs R, Skarbnik A, Tuncer H, Pagel J, Brander D, Cheson B, Barr P, Roeker LE, Pu J, Shah NN, Goy A, Schuster SJ, Lamanna N, Sehgal A, Tam CS, Shadman M. The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy. Blood Lymphat Cancer. 2020;10:1-5. PMCID: PMC7473982

71. Cronk RJ, Zurko J, Shah NN. Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma. Cancers (Basel). 2020 Sep 05;12(9). PMCID: PMC7564024

72. Roeker LE, Dreger P, Brown JR, Lahoud OB, Eyre TA, Brander DM, Skarbnik A, Coombs CC, Kim HT, Davids M, Manchini ST, George G, Shah N, Voorhees TJ, Orchard KH, Walter HS, Arumainathan AK, Sitlinger A, Park JH, Geyer MB, Zelenetz AD, Sauter CS, Giralt SA, Perales MA, Mato AR. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents. Blood Adv. 2020 Aug 25;4(16):3977-3989. PMCID: PMC7448605

73. Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, Cunningham A, Hamadani M, Fenske TS, Dropulić B, Orentas R, Hari P. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020 Oct;26(10):1569-1575.

74. Cuneo A, Mato AR, Rigolin GM, Piciocchi A, Gentile M, Laurenti L, Allan JN, Pagel JM, Brander DM, Hill BT, Winter A, Lamanna N, Tam CS, Jacobs R, Lansigan F, Barr PM, Shadman M, Skarbnik AP, Pu JJ, Sehgal AR, Schuster SJ, Shah NN, Ujjani CS, Roeker L, Orlandi EM, Billio A, Trentin L, Spacek M, Marchetti M, Tedeschi A, Ilariucci F, Gaidano G, Doubek M, Farina L, Molica S, Di Raimondo F, Coscia M, Mauro FR, de la Serna J, Medina Perez A, Ferrarini I, Cimino G, Cavallari M, Cucci R, Vignetti M, Foà R, Ghia P, GIMEMA, European Research Initiative (ERIC) on CLL, US study group. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. Cancer Med. 2020 Nov;9(22):8468-8479. PMCID: PMC7666748

75. Shah NN, Hamadani M. Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma? J Clin Oncol. 2021 Feb 10;39(5):487-498.

76. Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR, Alencar A, Lech-Maranda E, Wierda WG, Coombs CC, Gerson JN, Ghia P, Le Gouill S, Lewis DJ, Sundaram S, Cohen JB, Flinn IW, Tam CS, Barve MA, Kuss B, Taylor J, Abdel-Wahab O, Schuster SJ, Palomba ML, Lewis KL, Roeker LE, Davids MS, Tan XN, Fenske TS, Wallin J, Tsai DE, Ku NC, Zhu E, Chen J, Yin M, Nair B, Ebata K, Marella N, Brown JR, Wang M. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021 Mar 06;397(10277):892-901. PMCID: PMC11758240

77. Zurko J, Chaney K, Astle JM, Johnson BD, Hari P, Shah NN. PD-1 blockade after bispecific LV20.19 CAR T modulates CAR T-cell immunophenotype without meaningful clinical response. Haematologica. 2021 Oct 01;106(10):2788-2790. PMCID: PMC8485669

78. Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang XY, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, Ambinder RF, Anasetti C, Perales MA, Spellman SR, Howard A, Komanduri KV, Luznik L, Norkin M, Pidala JA, Ratanatharathorn V, Confer DL, Devine SM, Horowitz MM, Bolaños-Meade J. National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. J Clin Oncol. 2021 Jun 20;39(18):1971-1982. PMCID: PMC8260905

79. Scordo M, Wang TP, Ahn KW, Chen Y, Ahmed S, Awan FT, Beitinjaneh A, Chen A, Chow VA, Dholaria B, Epperla N, Farooq U, Ghosh N, Grover N, Hamad N, Hildebrandt GC, Holmberg L, Hong S, Inwards DJ, Jimenez-Jimenez A, Karmali R, Kenkre VP, Khimani F, Klyuchnikov E, Krem MM, Munshi PN, Nieto Y, Prestidge T, Ramakrishnan Geethakumari P, Rezvani AR, Riedell PA, Seo S, Shah NN, Solh M, Yared JA, Kharfan-Dabaja MA, Herrera A, Hamadani M, Sauter CS. Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. JAMA Oncol. 2021 Jul 01;7(7):993-1003. PMCID: PMC8283558

80. Cutler C, Lee SJ, Arai S, Rotta M, Zoghi B, Lazaryan A, Ramakrishnan A, DeFilipp Z, Salhotra A, Chai-Ho W, Mehta R, Wang T, Arora M, Pusic I, Saad A, Shah NN, Abhyankar S, Bachier C, Galvin J, Im A, Langston A, Liesveld J, Juckett M, Logan A, Schachter L, Alavi A, Howard D, Waksal HW, Ryan J, Eiznhamer D, Aggarwal SK, Ieyoub J, Schueller O, Green L, Yang Z, Krenz H, Jagasia M, Blazar BR, Pavletic S. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. Blood. 2021 Dec 02;138(22):2278-2289. PMCID: PMC8641099

81. Dhakal B, Thapa B, Dong H, Tarima S, Chhabra S, D'Souza A, Drobyski W, Abid M, Shah N, Fenske T, Longo W, Hari P, Hamadani M. Budesonide Prophylaxis Reduces the Risk of Engraftment Syndrome After Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2021 Oct;21(10):e775-e781.

82. Palen K, Zurko J, Johnson BD, Hari P, Shah NN. Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model? Cytotherapy. 2021 Nov;23(11):985-990.

83. Ahmed G, Hamadani M, Shah NN. CAR T-cell therapy for secondary CNS DLBCL. Blood Adv. 2021 Dec 28;5(24):5626-5630. PMCID: PMC8714710

84. Luo T, Zurko J, Astle J, Shah NN. Mimicking Myelodysplastic Syndrome: Importance of Differential Diagnosis. Case Rep Hematol. 2021;2021:9661765. PMCID: PMC8648467

85. Zurko JC, Johnson BD, Aschenbrenner E, Fenske TS, Hamadani M, Hari P, Shah NN. Use of Early Intrathecal Therapy to Manage High-Grade Immune Effector Cell-Associated Neurotoxicity Syndrome. JAMA Oncol. 2022 May 01;8(5):773-775. PMCID: PMC8914887

86. Shah NN, Harrington AM. Hemophagocytosis in cerebrospinal fluid after CAR T-cell therapy. Blood. 2022 Feb 17;139(7):1116.

87. Abid MB, Rubin M, Ledeboer N, Szabo A, Longo W, Mohan M, Shah NN, Fenske TS, Abedin S, Runaas L, D'Souza A, Chhabra S, Dhakal B, Hamadani M. Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients. Cancer Cell. 2022 Apr 11;40(4):340-342. PMCID: PMC8864440

88. Johnson AK, Lorimer EL, Szabo A, Wu R, Shah NN, D'Souza A, Chhabra S, Hamadani M, Dhakal B, Hari P, Rao S, Carlson K, Williams CL, Knight JM. Rap1A, Rap1B, and β-Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol. Yale J Biol Med. 2022 Mar;95(1):45-56. PMCID: PMC8961707

89. Knight JM, Szabo A, Arapi I, Wu R, Emmrich A, Hackett E, Sauber G, Yim S, Johnson B, Hari P, Schneider D, Dropulic B, Cusatis RN, Cole SW, Hillard CJ, Shah NN. Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy. Commun Med (Lond). 2022;2(1):49. PMCID: PMC9098435

90. Zurko JC, Xu H, Chaney K, Schneider D, Szabo A, Hari P, Johnson BD, Shah NN. Bispecific targeting of CD20 and CD19 increases polyfunctionality of chimeric antigen receptor T-cell products in B-cell malignancies. Cytotherapy. 2022 Aug;24(8):767-773.

91. Ahmed G, Bhasin-Chhabra B, Szabo A, Shah NN, Longo W, Dhakal B, Chhabra S, D'Souza A, Fenske TS, Hamadani M. Impact of Chronic Kidney Disease and Acute Kidney Injury on Safety and Outcomes of CAR T-Cell Therapy in Lymphoma Patients. Clin Lymphoma Myeloma Leuk. 2022 Nov;22(11):863-868.

92. Mohan, M., S. Nagavally, N.N. Shah, L. Michaelis, S. Chhabra, A.D. Souza, S. Abedin, L. Runaas, G.S. Guru Murthy, W. Longo, M. Hamadani, B. Dhakal, P. Hari, and T.S. Fenske, Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies. Clin Lymphoma Myeloma Leuk, 2022. 22(7): p. e495-e497.

93. Furqan F, Shah NN. Bispecific CAR T-cells for B-cell Malignancies. Expert Opin Biol Ther. 2022 Aug;22(8):1005-1015.

94. Zurko J, Ramdial J, Shadman M, Ahmed S, Szabo A, Iovino L, Tomas AA, Sauter C, Perales MA, Shah NN, Acharya UH, Jacobson C, Soiffer RJ, Wang T, Komanduri KV, Jaglowski S, Kittai AS, Denlinger N, Iqbal M, Kharfan-Dabaja MA, Ayala E, Chavez J, Jain M, Locke FL, Samara Y, Budde LE, Mei MG, Pia AD, Feldman T, Ahmed N, Jacobs R, Ghosh N, Dholaria B, Oluwole OO, Hess B, Hassan A, Kenkre VP, Reagan P, Awan F, Nieto Y, Hamadani M, Herrera AF. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. Haematologica. 2023 Jan 01;108(1):98-109. PMCID: PMC9827150

95. Maziarz RT, Diaz A, Miklos DB, Shah NN. Perspective: An International Fludarabine Shortage: Supply Chain Issues Impacting Transplantation and Immune Effector Cell Therapy Delivery. Transplant Cell Ther. 2022 Nov;28(11):723-726.

96. Zurko JC, Fenske TS, Johnson BD, Bucklan D, Szabo A, Xu H, Chaney K, Hamadani M, Hari P, Shah NN. Long-term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T-cells. Am J Hematol. 2022 Dec;97(12):1580-1588.

97. Knight JM, Hackett E, Szabo A, Wu R, Sauber G, Johnson B, Cusatis RN, Aughey E, Cole SW, Hillard CJ, Shah NN. Associations between socioeconomic status and bispecific LV20.19 CAR T-cell therapy outcomes. Haematologica. 2023 Feb 01;108(2):588-593. PMCID: PMC9890001

98. Zurko J, Nizamuddin I, Epperla N, David K, Cohen JB, Moyo TK, Ollila T, Hess B, Roy I, Ferdman R, Liu J, Chowdhury SM, Romancik J, Bhansali RS, Harris EI, Sorrell M, Masel R, Kittai AS, Denlinger N, Sigmund AM, Fitzgerald L, Galvez C, Ma S, Winter J, Pro B, Gordon LI, Danilov A, Stephens D, Shah NN, Kenkre V, Barta SK, Torka P, Shouse G, Karmali R. Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL. Blood Adv. 2023 Jun 27;7(12):2657-2669. PMCID: PMC10333741

99. Chhabra S, Szabo A, Clurman A, McShane K, Waters N, Eastwood D, Samanas L, Fei T, Armijo G, Abedin S, Longo W, Hari P, Hamadani M, Shah NN, Runaas L, Jerkins JH, Van den Brink M, Peled JU, Drobyski WR. Mitigation of gastrointestinal graft-<i>versus</i>-host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination. Haematologica. 2023 Jan 01;108(1):250-256. PMCID: PMC9827178

100. Furqan F, Shah NN. Multispecific CAR T Cells Deprive Lymphomas of Escape via Antigen Loss. Annu Rev Med. 2023 Jan 27;74:279-291.

101. Eyre TA, Shah NN, Dreyling M, Jurczak W, Wang Y, Cheah CY, Song Y, Gandhi M, Chay C, Sharman J, Andorsky DJ, Messersmith HM, Ruppert AS, Muthig VA, Ito R, Wang ML. BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma. Future Oncol. 2022 Nov;18(36):3961-3969.

102. Furqan F, Maring M, Szabo A, Fenske TS, Hamadani M, Shah NN. Salvage polatuzumab and allogeneic transplant rescue patients with B-cell lymphoma failing CAR T-cell therapy. Blood Adv. 2023 Jun 13;7(11):2463-2467. PMCID: PMC10241849

103. Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang XY, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, Ambinder RF, Anasetti C, Perales MA, Spellman SR, Howard A, Komanduri KV, Luznik L, Norkin M, Pidala JA, Ratanatharathorn V, Confer DL, Devine SM, Horowitz MM, Bolaños-Meade J. Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial. Transplant Cell Ther. 2023 Mar;29(3):208.e1-208.e6. PMCID: PMC9992261

104. Sasu BJ, Opiteck GJ, Gopalakrishnan S, Kaimal V, Furmanak T, Huang D, Goswami A, He Y, Chen J, Nguyen A, Balakumaran A, Shah NN, Hamadani M, Bone KM, Prashad S, Bowen MA, Pertel T, Embree HD, Gidwani SG, Chang D, Moore A, Leonard M, Amado RG. Detection of chromosomal alteration after infusion of gene-edited allogeneic CAR T cells. Mol Ther. 2023 Mar 01;31(3):676-685. PMCID: PMC10014221

105. Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, Frigault MJ, Hill JA, Jain MD, Johnson WT, Lin Y, Mahadeo KM, Maron GM, Marsh RA, Neelapu SS, Nikiforow S, Ombrello AK, Shah NN, Talleur AC, Turicek D, Vatsayan A, Wong SW, Maus MV, Komanduri KV, Berliner N, Henter JI, Perales MA, Frey NV, Teachey DT, Frank MJ, Shah NN. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. PMCID: PMC10330221

106. Dickinson MJ, Barba P, Jäger U, Shah NN, Blaise D, Briones J, Shune L, Boissel N, Bondanza A, Mariconti L, Marchal AL, Quinn DS, Yang J, Price A, Sohoni A, Treanor LM, Orlando EJ, Mataraza J, Davis J, Lu D, Zhu X, Engels B, Moutouh-de Parseval L, Brogdon JL, Moschetta M, Flinn IW. A Novel Autologous CAR-T Therapy, YTB323, with Preserved T-cell Stemness Shows Enhanced CAR T-cell Efficacy in Preclinical and Early Clinical Development. Cancer Discov. 2023 Sep 06;13(9):1982-1997. PMCID: PMC10481129

107. Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, Riedell PA, Shah NN, Nath R, Fakhri B, Stephens DM, Ma S, Feldman T, Solomon SR, Schuster SJ, Perna SK, Tuazon SA, Ou SS, Papp E, Peiser L, Chen Y, Wierda WG. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet. 2023 Aug 19;402(10402):641-654. PMCID: PMC11753452

108. Wang ML, Jurczak W, Zinzani PL, Eyre TA, Cheah CY, Ujjani CS, Koh Y, Izutsu K, Gerson JN, Flinn I, Tessoulin B, Alencar AJ, Ma S, Lewis D, Lech-Maranda E, Rhodes J, Patel K, Maddocks K, Lamanna N, Wang Y, Tam CS, Munir T, Nagai H, Hernandez-Ilizaliturri F, Kumar A, Fenske TS, Seymour JF, Zelenetz AD, Nair B, Tsai DE, Balbas M, Walgren RA, Abada P, Wang C, Zhao J, Mato AR, Shah NN. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. J Clin Oncol. 2023 Aug 20;41(24):3988-3997. PMCID: PMC10461952

109. Mato AR, Woyach JA, Brown JR, Ghia P, Patel K, Eyre TA, Munir T, Lech-Maranda E, Lamanna N, Tam CS, Shah NN, Coombs CC, Ujjani CS, Fakhri B, Cheah CY, Patel MR, Alencar AJ, Cohen JB, Gerson JN, Flinn IW, Ma S, Jagadeesh D, Rhodes JM, Hernandez-Ilizaliturri F, Zinzani PL, Seymour JF, Balbas M, Nair B, Abada P, Wang C, Ruppert AS, Wang D, Tsai DE, Wierda WG, Jurczak W. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia. N Engl J Med. 2023 Jul 06;389(1):33-44.

110. Epperla N, Feng L, Shah NN, Fitzgerald L, Shah H, Stephens DM, Lee CJ, Ollila T, Shouse G, Danilov AV, David KA, Torka P, Hashmi H, Hess B, Barta SK, Romancik JT, Cohen JB, Annunzio K, Kittai AS, Reneau J, Zurko J, Nizamuddin IA, Winter JN, Gordon LI, Ma S, Patel R, Nastoupil L, Ahmed S, Karmali R. Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study. J Hematol Oncol. 2023 Nov 09;16(1):111. PMCID: PMC10633964

111. Kenkel TJ, Sridhar N, Hammons LR, Hintzke M, Shah NN. Bone Marrow Aplasia after CAR-T-Cell Therapy for Relapsed/Refractory Burkitt's Lymphoma. Med Sci (Basel). 2023 Oct 12;11(4). PMCID: PMC10594436

112. Hammons L, Haider S, Portuguese AJ, Banerjee R, Szabo A, Pasquini M, Chhabra S, Radhakrishnan S, Mohan M, Narra R, Dong J, Janz S, Shah NN, Hamadani M, D'Souza A, Hari P, Dhakal B. Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantation. Br J Haematol. 2024 Mar;204(3):887-891.

113. Bowers JT, Anna J, Bair SM, Annunzio K, Epperla N, Pullukkara JJ, Gaballa S, Spinner MA, Li S, Messmer MR, Nguyen J, Ayers EC, Wagner CB, Hu B, Di M, Huntington SF, Furqan F, Shah NN, Chen C, Ballard HJ, Hughes ME, Chong EA, Nasta SD, Barta SK, Landsburg DJ, Svoboda J. Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort. Blood Adv. 2023 Nov 14;7(21):6630-6638. PMCID: PMC10628810

114. Abid MB, Rubin M, Szabo A, Longo W, Fenske TS, McCoy C, Lorge A, Abedin S, D'Souza A, Dhakal B, Shah NN, Hamadani M. Efficacy of Multiple SARS-CoV-2 Vaccine Doses in Patients with B Cell Hematologic Malignancies Receiving Chimeric Antigen Receptor T Cell Therapy: A Contemporary Cohort Analysis. Transplant Cell Ther. 2024 Mar;30(3):285-297.

115. Crombie JL, Graff T, Falchi L, Karimi YH, Bannerji R, Nastoupil L, Thieblemont C, Ursu R, Bartlett N, Nachar V, Weiss J, Osterson J, Patel K, Brody J, Abramson JS, Lunning M, Shah NN, Ayed A, Kamdar M, Parsons B, Caimi P, Flinn I, Herrera A, Sharman J, McKenna M, Armand P, Kahl B, Smith S, Zelenetz A, Budde LE, Hutchings M, Phillips T, Dickinson M. Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy. Blood. 2024 Apr 18;143(16):1565-1575.

116. Rezazadeh A, Pruett J, Detzner A, Edwin N, Hamadani M, Shah NN, Fenske TS. Immunoglobulin High Throughput Sequencing (Ig-HTS) Minimal Residual Disease (MRD) Analysis is an Effective Surveillance Tool in Patients With Mantle Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2024 Apr;24(4):254-259.

117. Karmali R, Galvez C, Hamadani M, Gordon L, Winter J, Ma S, Nelson V, Fenske TS, Shah NN, Jagadeesh D, Klein A, Helenowski I, Chen R, Mi X, Petrich A, Evens AM, Pro B. A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen. Blood Adv. 2024 Apr 09;8(7):1612-1620. PMCID: PMC10987893

118. Chhabra S, Jerkins JH, Monahan K, Szabo A, Shah NN, Abedin S, Runaas L, Fenske TS, Pasquini MC, Shaw BE, Drobyski WR, Saber W, D'Souza A, Dhakal B, Mohan M, Longo W, Hamadani M. Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2024 Mar;59(3):373-379.

119. Furqan F, Shah NN. The role of noncovalent BTK inhibitors in the era of covalent BTK inhibitors. Clin Adv Hematol Oncol. 2024 Apr;22(3):140-147.

120. Melody M, Epperla N, Shouse G, Romancik J, Allen P, Moyo TK, Kenkre V, Ollila T, Fitzgerald L, Hess B, David K, Herr MM, Odetola O, Lin A, Moreira J, Ma S, Winter JN, Roy I, Stephens D, Danilov A, Shah NN, Barta SK, Cortese M, Cohen JB, Gordon LI, Karmali R. Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy. Blood Adv. 2024 May 28;8(10):2327-2331. PMCID: PMC11126789

121. Karmali R, Machhi R, Epperla N, Shouse G, Romancik J, Moyo TK, Kenkre V, Ollila TA, Fitzgerald L, Hess B, David K, Roy I, Zurko J, Chowdhury SM, Annunzio K, Ferdman R, Bhansali RS, Harris EI, Liu J, Nizamuddin I, Ma S, Moreira J, Winter J, Pro B, Stephens DM, Danilov A, Shah NN, Cohen JB, Barta SK, Torka P, Gordon LI. Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy. Blood Adv. 2024 May 28;8(10):2592-2599. PMCID: PMC11145749

122. Furqan, F., K. Baird, M. Kacar, A.S. Surapaneni, U. Kemmo Tsafack, A. Szabo, J. Svoboda, B.T. Hill, J.T. Romancik, and N.N. Shah, Multicenter Study to Assess the Outcomes and Prognosis of Richter's Transformation in the Era of Novel Agents and Cell Therapy. Blood, 2023. 142(Supplement 1): p. 4486-4486.

123. Watt KD, Rolak S, Foley DP, Plichta JK, Pruthi S, Farr D, Zwald FO, Carvajal RD, Dudek AZ, Sanger CB, Rocco R, Chang GJ, Dizon DS, Langstraat CL, Teoh D, Agarwal PK, Al-Qaoud T, Eggener S, Kennedy CC, D'Cunha J, Mohindra NA, Stewart S, Habermann TH, Schuster S, Lunning M, Shah NN, Gertz MA, Mehta J, Suvannasankha A, Verna E, Farr M, Blosser CD, Hammel L, Al-Adra DP. Cancer Surveillance in Solid Organ Transplant Recipients With a Pretransplant History of Malignancy: Multidisciplinary Collaborative Expert Opinion. Transplantation. 2024 Dec 01;108(12):2336-2350.

124. Wierda WG, Shah NN, Cheah CY, Lewis D, Hoffmann MS, Coombs CC, Lamanna N, Ma S, Jagadeesh D, Munir T, Wang Y, Eyre TA, Rhodes JM, McKinney M, Lech-Maranda E, Tam CS, Jurczak W, Izutsu K, Alencar AJ, Patel MR, Seymour JF, Woyach JA, Thompson PA, Abada PB, Ho C, McNeely SC, Marella N, Nguyen B, Wang C, Ruppert AS, Nair B, Liu H, Tsai DE, Roeker LE, Ghia P. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study. Lancet Haematol. 2024 Sep;11(9):e682-e692.

125. Shadman M, Ahn KW, Kaur M, Lekakis L, Beitinjaneh A, Iqbal M, Ahmed N, Hill B, Hossain NM, Riedell P, Gopal AK, Grover N, Frigault M, Brammer J, Ghosh N, Merryman R, Lazaryan A, Ram R, Hertzberg M, Savani B, Awan F, Khimani F, Ahmed S, Kenkre VP, Ulrickson M, Shah N, Kharfan-Dabaja MA, Herrera A, Sauter C, Hamadani M. Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission. Blood Cancer J. 2024 Jul 08;14(1):108. PMCID: PMC11231252

126. Roeker LE, Woyach JA, Cheah CY, Coombs CC, Shah NN, Wierda WG, Patel MR, Lamanna N, Tsai DE, Nair B, Wang C, Zhao X, Liu D, Radtke D, Chapman S, Marella N, McNeely SC, Brown JR. Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial. Blood. 2024 Sep 26;144(13):1374-1386. PMCID: PMC11451378

127. Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, Riedell PA, Shah NN, Nath R, Fakhri B, Stephens DM, Ma S, Feldman T, Solomon SR, Schuster SJ, Perna SK, Tuazon S, Ou S, Papp E, Chen Y, Wierda W. 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023. Hematol Oncol. 2023 Jun;41 Suppl 2:60-62.

128. Peloquin S, Cymbalista F, Dreyling M, Shah NN, Murray S, Del Fiacco R, Muehlenbein CE, Lazure P. Knowledge, skills, and confidence gaps impacting treatment decision making in relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma: a quantitative survey study in France, Germany, and the United States. BMC Cancer. 2024 Aug 13;24(1):1003. PMCID: PMC11321192

129. Shah NN, Wang M, Roeker LE, Patel K, Woyach JA, Wierda WG, Ujjani CS, Eyre TA, Zinzani PL, Alencar AJ, Ghia P, Lamanna N, Hoffmann MS, Patel MR, Flinn I, Gerson JN, Ma S, Coombs CC, Cheah CY, Lech-Maranda E, Fakhri B, Kim WS, Barve MA, Cohen JB, Jurczak W, Munir T, Thompson MC, Tsai DE, Bao K, Cangemi NA, Kherani JF, Walgren RA, Han H, Ruppert AS, Brown JR. Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial. Haematologica. 2025 Jan 01;110(1):92-102. PMCID: PMC11694105

130. Akhtar OS, Arshad S, Lian Q, Ahn KW, D'Souza A, Dhakal B, Mohan M, Pasquini M, Longo W, Shah NN, Fenske TS, Hamadani M. Comparison of Thiotepa-based Conditioning Regimens for Older Adults with Primary Diffuse Large B-cell Lymphoma of the Central Nervous System Undergoing Autologous Hematopoietic Cell Transplantation. Transplant Cell Ther. 2024 Dec;30(12):1191.e1-1191.e8. PMCID: PMC12483827

131. Urbano-Ispizua Á, Shah NN, Kekre N. Point-of-care CAR T manufacturing solutions: can 1 model fit all? Blood Adv. 2024 Dec 10;8(23):6133-6136. PMCID: PMC11707413

132. Furqan F, Bhatlapenumarthi V, Dhakal B, Fenske TS, Farrukh F, Longo W, Akhtar O, D'Souza A, Pasquini M, Guru Murthy GS, Runaas L, Abedin S, Mohan M, Shah NN, Hamadani M. Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention. Blood Adv. 2024 Aug 27;8(16):4320-4329. PMCID: PMC11372811

133. Roeker LE, Coombs CC, Shah NN, Jurczak W, Woyach JA, Cheah CY, Patel K, Maddocks K, Wang Y, Zinzani PL, Munir T, Koh Y, Thompson MC, Muehlenbein CE, Wang C, Sizelove R, Abhyankar S, Hasanabba S, Tsai DE, Eyre TA, Wang M. Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies. Acta Haematol. 2025;148(2):180-197. PMCID: PMC11617602

134. Kearl TJ, Furqan F, Shah NN. CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms. Cancer Metastasis Rev. 2024 Dec 01;44(1):12.

135. Kwiatek M, Murthy GSG, Hoffmann M, Tessoulin B, Danilov A, Alencar AJ, Shah NN, Ghesquieres H, Le Gouill S, Jurczak W, Han H, Yuen E, Patel V, Guo-Avrutin Y, Pauff JM, Roeker LE. A First-in-Human Phase I Study of LOXO-338, an Oral Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic Malignancies Clinical Lymphoma, Myeloma and Leukemia. 2025.

136. Shah NN, Colina AS, Johnson BD, Szabo A, Furqan F, Kearl T, Schneider D, Vargas-Cortes M, Schmeling JL, Dwinell MB, Palen K, Longo W, Hematti P, Zamora AE, Hari P, Bucklan D, Cunningham A, Hamadani M, Fenske TS. Phase I/II Study of Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed, Refractory Mantle Cell Lymphoma. J Clin Oncol. 2025 Jul 10;43(20):2285-2295.

137. Karmali R, Shouse G, Torka P, Moyo TK, Romancik J, Barta SK, Bhansali R, Cohen JB, Shah NN, Zurko J, Kenkre VP, Hess B, Stephens DM, Fitzgerald L, Ollila T, Tabiti B, Roy I, Ma S, Winter J, Pro B, Moreira J, Danilov AV, David K, Gordon LI, Epperla N. Double hit &amp; double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy. Blood Cancer J. 2025 Mar 26;15(1):43. PMCID: PMC11947441

138. Frigault MJ, Maziarz RT, Park JH, Lazaryan A, Shah NN, Svoboda J, Lekakis L, Reshef R, Phillips CL, Burke L, Lei J, Pratta M, Morariu-Zamfir R, DiPersio JF. Itacitinib for the prevention of IEC therapy-associated CRS: results from the 2-part phase 2 INCB 39110-211 study. Blood. 2025 Jul 24;146(4):422-436.

139. Kwiatek M, Murthy GSG, Hoffmann M, Tessoulin B, Danilov A, Alencar AJ, Shah NN, Ghesquieres H, Le Gouill S, Jurczak W, Han H, Yuen E, Patel V, Guo-Avrutin Y, Pauff JM, Roeker LE. A First-in-Human Phase I Study of LOXO-338, an Oral Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic Malignancies. Clin Lymphoma Myeloma Leuk. 2025 Jul;25(7):512-519.

140. Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, Frigault MJ, Hill JA, Jain MD, Johnson WT, Lin Y, Mahadeo KM, Maron GM, Marsh RA, Neelapu SS, Nikiforow S, Ombrello AK, Shah NN, Talleur AC, Turicek D, Vatsayan A, Wong SW, Maus MV, Komanduri KV, Berliner N, Henter JI, Perales MA, Frey NV, Teachey DT, Frank MJ, Shah NN. Erratum to 'Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome'[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9]. Transplant Cell Ther. 2026 Jun;32(6):765-766. PMCID: PMC12677140

141. Brown JR, Nguyen B, Desikan SP, Won H, Tantawy SI, McNeely SC, Marella N, Randeria HS, Hanson LM, Parker A, Botelho SC, Woyach JA, Patel K, Tam CS, Eyre TA, Cheah CY, Shah NN, Ghia P, Jurczak W, Balbas M, Nair B, Abada P, Wang C, Wang D, Roeker LE, Gandhi V, Wierda WG. Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia. Blood. 2026 Jan 01;147(1):24-34. PMCID: PMC12824664

142. Shah NN, Zinzani PL, Wang M, Nasta SD, Lech-Maranda E, Ogawa Y, Fakhri B, Kuss B, Miyashita K, Patel K, Coombs CC, Ma S, Patel MR, Barve MA, Tessoulin B, Stathis A, Ennishi D, Hashimoto D, Kojima K, Zelenetz AD, Cohen JB, Vose JM, Maddocks KJ, Munir T, Sun F, Bian Y, Balbas M, Tsai DE, Abada P, Cheah CY. Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study. Blood Adv. 2025 Dec 09;9(23):5954-5964. PMCID: PMC12686794

143. Nadiminti KV, Ahn KW, Patel J, Lian Q, Bezerra E, Chen A, Ganguly S, Gergis U, Hashmi H, Kharfan-Dabaja MA, Kuruvilla J, Lekakis L, Locke FL, Murthy H, Mousthafa MA, Perales MA, Pophali P, Riedell PA, Shah NN, Wang T, Pasquini M, Hamadani M, Turtle CJ, Herrera AF, Shadman M. Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: A CIBMTR Analysis. Transplant Cell Ther. 2025 Dec;31(12):1000.e1-1000.e11. PMCID: PMC12718520

144. Annunzio K, Shah NN. Sequencing CAR-Ts in Relapsed DLBCL: Is More Always Better? Transplant Cell Ther. 2025 Nov;31(11):849-850.

145. Runaas L, Fank S, Palen K, Szabo A, Rein LE, Ying G, Salzman N, Samanas L, Abedin S, Chhabra S, Hamadani M, Longo W, Shah NN, Haber J, Gradissimo A, Waters N, Peled JU, Johnson B, Kearl T, Drobyski WR. Tildrakizumab for the prophylaxis of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2026 Apr 28;10(8):2698-2710. PMCID: PMC13101680

146. Coombs CC, Woyach JA, Brown JR, Ghia P, Roeker LE, Patel K, Eyre TA, Tam CS, Seymour JF, Shah NN, Flinn I, Cheah CY, Ma S, Rhodes JM, Izutsu K, Jurczak W, Wierda WG, Hess LM, Bhandari NR, Loubert A, Abada PB, Lamanna N. Patient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis. Curr Med Res Opin. 2025 Dec;41(12):2323-2338.

147. Patel K, Vose JM, Nasta SD, Brown JR, Maddocks KJ, Woyach JA, Shah NN, Fakhri B, Tessoulin B, Ma S, Jagadeesh D, Lech-Maranda E, Coombs CC, Patel MR, Rhodes JM, Ujjani C, Hoffmann MS, Cheah CY, Munir T, Lewis D, Scarfò L, Eyre TA, Alencar A, Cohen JB, Zelenetz AD, Tsai DE, Li M, Bian Y, Abada P, Balbas M, Zinzani PL. Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study. Blood Adv. 2026 Apr 14;10(7):2441-2451. PMCID: PMC13083716

148. Aughey E, Shah NN, Hillard CJ, Rentscher KE, Hamadani M, Longo W, Devata S, Knight JM, Cusatis R. Financial Toxicity in a Phase I/II Trial of LV20.19 CAR-T Cell for B-cell Malignancies: A Longitudinal, Qualitative Study. Transplant Cell Ther. 2026 May;32(5):621.e1-621.e11. PMCID: PMC12952239

149. Locke FL, Nikiforow S, Frigault MJ, Maloney DG, Davila M, Miklos DB, Lin Y, Vong J, Shah NN, Neelapu SS, Welch J, Ng E, Jacobson C, Maus MV. Recommendations for Defining Chimeric Antigen Receptor T-Cell (CAR T) Dose-Limiting Toxicities (DLTs) for Future Early-Phase CAR T Therapy Studies. Transplant Cell Ther. 2025 Nov 07.

150. Wang JS, Ellsworth BL, Melody M, Epperla N, Stephens D, Romancik J, Cortese M, Bhansali R, Moyo TK, Kenkre V, Ollila T, Hess B, Fitzgerald L, Shouse G, Matasar M, Herr MM, Davis J, Jesme C, Pelcovits AR, Moreira J, Lin AY, Ma S, Winter JN, Danilov AV, Shah NN, Barta SK, Cohen JB, Gordon LI, Grover N, Karmali R. Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium. Blood Adv. 2026 Feb 10;10(3):725-732. PMCID: PMC12874299

151. Shah NN. Everybody gets a CAR! But do they need it? Blood. 2026 Mar 19;147(12):1244-1246.

152. Shah V, Womack JA, Palen K, Johnson BD, Hematti P, Kearl TJ, Shah NN, Terhune SS, Dash RK. Data-driven computational modeling of CAR-T cell function. Front Immunol. 2026;17:1707783. PMCID: PMC13212496

153. Stollenwerk TM, Barnett ME, Steineck AS, Shah NN, Knight JM. Mania and psychosis following chimeric antigen receptor T-cell therapy: A report of two cases and mechanistic discussion. Brain Behav Immun Health. 2026 Jul;54:101251. PMCID: PMC13156647

1. Narra, R.K. and N.N. Shah, Chapter 15 - Allogenic Transplant for Non-Hodgkin Lymphoma, in Hematopoietic Cell Transplantation for Malignant Conditions, Q. Bashir and M. Hamadani, Editors. 2019, Elsevier. p. 209-229.

2. Shah, N.N., A. Levin, V. Radhakrishnan, and P. Hari, Cellular Therapy, in Contemporary Bone Marrow Transplantation, M. Chandy, V.S. Radhakrishnan, and R. Sukumaran, Editors. 2020, Springer International Publishing: Cham. p. 1-21.

3. Khan, I., N.N. Shah, M. Ulrickson. Hematopoietic cell transplantation and cellular therapy, in American Society of Hematology Self-Assessment Program. 2022, American Society of Hematology Washington, DC. Chp14.

1. Shah, NN., Zhu, F., Xu, H., Schneider, D., Orentas, R., Dropulic, B., Hari, P., Keever-Taylor, C. Dual Targeted CD20/19 CAR-T cell Production Using the ClinicMACS Prodigy System. Oral Presentation. Medical College of Wisconsin Research Day. Milwaukee, WI, 3/10/17. ORAL.

2. Shah, NN., K.W. Ahn, C. Litovich, A. Sureda, S.M. Smith, T.S. Fenske, and M. Hamadani, Outcomes of Patients 65 Years and Older with Non-Hodgkin Lymphoma Receiving Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation Compared to Patients 55-64 Years of Age: A CIBMTR Analysis. Biology of Blood and Marrow Transplantation, 2018. 24(3): p. S77-S78. ORAL.

3. Chen, Y.-B., N.N. Shah, A.S. Renteria, C.S. Cutler, J. Jansson, M. Akbari, C. Chen, S. Quadri, A. Parfionovas, and S. Devine, A Phase 1b Study of Intravenous Vedolizumab Plus Standard of Care for Graft-Versus-Host Disease Prophylaxis in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies: 6-Month Results. Blood, 2018. 132(Suppl 1): p. 605-605. ORAL.

4. Jagasia, M., M.-A. Perales, M.A. Schroeder, H. Ali, N.N. Shah, Y.-B. Chen, M.C. Arbushites, F. Dawkins, C. Tian, and H.J. Khoury, Results from REACH1, a Single-Arm Phase 2 Study of Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease. Blood, 2018. 132(Suppl 1): p. 601-601. ORAL.

5. Solomon, S.R., A. St. Martin, N.N. Shah, G. Fatobene, M. Al Malki, K.K. Ballen, A. Bashey, N. Bejanyan, J. Bolaños-Meade, C.G. Brunstein, Z. Defilipp, R.E. Champlin, E.J. Fuchs, M. Hamadani, P. Hematti, C.G. Kanakry, J.P. McGuirk, I.K. McNiece, S.O. Ciurea, M.C. Pasquini, V. Rocha, R. Romee, S.S. Patel, S. Vasu, E.K. Waller, J.R. Wingard, M.-J. Zhang, and M. Eapen, T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes. Blood, 2018. 132(Suppl 1): p. 1015-1015. ORAL.

6. Jagasia, M., H. Ali, M.A. Schroeder, N.N. Shah, Y.-B. Chen, F. Dawkins, M. Arbushites, C. Tian, and M.-A. Perales, Ruxolitinib in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Vs-Host Disease: Results from the Phase 2 REACH1 Trial. Biology of Blood and Marrow Transplantation, 2019. 25(3, Supplement): p. S52. ORAL.

7. Zhu, F., N.N. Shah, D. Schneider, H. Xu, K. Chaney, L. Luib, C. Keever-Taylor, B. Dropulic, R. Orentas, P. Hari, and B.D. Johnson, Automated Manufacturing of CD20.19 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cells at an Academic Center for a Phase I Clinical Trial in Relapsed, Refractory NHL. Biology of Blood and Marrow Transplantation, 2019. 25(3): p. S62. ORAL.

8. Shah, N.N., F. Zhu, C. Keever-Taylor, D. Schneider, W. Kruger, A. Worden, M. Hamadani, T.S. Fenske, B.D. Johnson, B. Dropulic, R. Orentas, and P. Hari, Clinical Results of a First-in-Human Phase 1 Study of Point-of-Care Manufactured Bispecific Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CAR-20.19-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma (NHL). Biology of Blood and Marrow Transplantation, 2019. 25(3): p. S63-S64. ORAL.

9. Hamadani, M., Ahn KW., Litovich, C., Fenske, T., Sureda, A., Kharfan-Dabaja, M., Shah, NN. Allogeneic Hematopoietic Transplantation IN Elderly Non-hodgkin Lymphoma Patients: A Time Trends Analysis from the CIBMTR. European Bone Marrow Transplant Annual Meeting, 2019. ORAL.

10. Shah, N.N., F. Zhu, C. Keever-Taylor, D. Schneider, W. Kruger, A. Worden, M. Hamadani, T.S. Fenske, B.D. Johnson, B. Dropulic, R. Orentas, and P. Hari, Clinical Results of a First-In-Human Phase 1 Study of Bispecific Anti-CD19, Anti-CD#) Chimeric Antigen Receptor Modified (LV20.19CAR) T cells for Relapsed, Refractory, Non-Hodgkin Lymphoma. European Bone Marrow Transplant Annual Meeting, 2019. ORAL.

11. Shah, N.N., F. Zhu, D. Schneider, C. Taylor, W. Krueger, A. Worden, W.L. Longo, M. Hamadani, T. Fenske, B. Johnson, B. Dropulic, R. Orentas, and P. Hari, Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma. Journal of Clinical Oncology, 2019. 37(15_suppl): p. 2510-2510. ORAL.

12. Eve, A, Shah, N.N., Spellacy, R..“Real Time IRB Review Process: A Smoother Pathway Towards Initial Approval” Onsemble Annual Meeting, 2019. ORAL.

13. Shah, N.N., K.W. Ahn, C. Litovich, T. Fenske, and M. Hamadani, Is autologous transplantation (autoHCT) in relapsed diffuse large B-cell lymphoma (DLBCL) patients achieving only a PET/CT positive partial remission (PR) appropriate in the CAR-T cell era? Journal of Clinical Oncology, 2020. 38(15_suppl): p. 8000-8000. ORAL.

14. Mato, A.R., J.M. Pagel, C.C. Coombs, N.N. Shah, N. Lamanna, E. Lech-Marańda, T.A. Eyre, J.A. Woyach, W.G. Wierda, C.Y. Cheah, L.E. Roeker, M.R. Patel, B. Fakhri, M. Barve, C.S. Tam, D.J. Lewis, J.N. Gerson, A.J. Alencar, J. Taylor, O. Abdel-Wahab, P. Ghia, S.J. Schuster, J. Chen, B. Nair, D. Tsai, N.C. Ku, M.S. Davids, J.R. Brown, and W. Jurczak, LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study. Blood, 2020. 136(Supplement 1): p. 35-37. ORAL.

15. Shaw, B.E., A. Jimenez-Jimenez, L.J. Burns, B. Logan, F. Khimani, B.C. Shaffer, N.N. Shah, A. Mussetter, X.-Y. Tang, J.M. McCarty, A. Alavi, N. Farhadfar, K. Jamieson, N.M. Hardy, H. Choe, R.F. Ambinder, C. Anasetti, M.-A. Perales, A. Howard, K.V. Komanduri, L. Luznik, M. Norkin, J. Pidala, V. Ratanatharathorn, D.L. Confer, S.M. Devine, M.M. Horowitz, and J. Bolanos-Meade, Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative. Blood, 2020. 136(Supplement 1): p. 48-49. ORAL.

16. Wang, M., N.N. Shah, A.J. Alencar, J.N. Gerson, M.R. Patel, B. Fakhri, W. Jurczak, X.N. Tan, K.L. Lewis, T.S. Fenske, C.C. Coombs, I.W. Flinn, D.J. Lewis, S. Le Gouill, M.L. Palomba, J.A. Woyach, J.M. Pagel, N. Lamanna, J.B. Cohen, M. Barve, P. Ghia, T.A. Eyre, M. Yin, B. Nair, D. Tsai, N.C. Ku, A. Mato, and C.Y. Cheah, LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenström's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study. Blood, 2020. 136(Supplement 1): p. 8-10. ORAL.

17. Kearl, T., A. Mei, R. Brown, B. Johnson, D. Schneider, B. Dropulic, P. Hari, N.N. Shah, and S. Malarkannan, Single-Cell RNA Sequencing Identifies Expression Patterns Associated with Clinical Responses to Dual-Targeted CAR-T Cell Therapy. Blood, 2020. 136(Supplement 1): p. 33-34. ORAL.

18. Shah, N.N., J.C. Zurko, D. Schneider, S. Yim, M. Hamadani, T.S. Fenske, B. Johnson, and P. Hari, Phase 1/2 Trial of IL7/IL15-Expanded Bispecific LV20.19 CAR T-Cells for Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma. Blood, 2021. 138(Supplement 1): p. 95-95. ORAL.

19. Hill, B.T., C.J. Roth, R. Kositsky, T. Dave, C. Love, M. McKinney, A. Galal, J.L. Neff, A. Mian, E. Kendall, S.L. Ondrejka, M. Chiaramonte, G. Bhagat, K. Ofori, R. Reshef, A.E. Kovach, T. Sethi, E.F. Mason, S. Bhaskar, O.O. Oluwole, C. Pallas, N. Ghosh, R. Ferdman, G.L. Chen, F.J. Hernandez-Ilizaliturri, J.C. Zurko, A. Cunningham, N.N. Shah, B. Hu, D.M. Stephens, M. Ghosh, N. Bailey, K. Patel, J.M. Pagel, K.K. Kannan, E.D. Hsi, R. Vaidya, A. Ip, A.H. Goy, S. Kambhampati, R.S. Ohgami, C. Andreadis, E. Thacker, C. Rozzi, C. Parker, L. Happ, and S.S. Dave, Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy. Blood, 2021. 138(Supplement 1): p. 165-165. ORAL.

20. Wang, M., N.N. Shah, A.J. Alencar, J.N. Gerson, M.R. Patel, B. Fakhri, W. Jurczak, X.N. Tan, K. Lewis, T.S. Fenske, C.C. Coombs, I.W. Flinn, D.J. Lewis, S. Le Gouill, M.L. Palomba, J.A. Woyach, J.M. Pagel, N. Lamanna, J.B. Cohen, M.A. Barve, P. Ghia, T.A. Eyre, P.L.L. Zinzani, C.S. Ujjani, Y. Koh, K. Izutsu, E. Lech-Marańda, C.S. Tam, S. Sundaram, M. Yin, B. Nair, M. Balbas, D. Tsai, A.R. Mato, and C.Y. Cheah, Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the Phase 1/2 BRUIN Study. Blood, 2021. 138(Supplement 1): p. 381-381. ORAL.

21. Flinn, I.W., U. Jaeger, N.N. Shah, D. Blaise, J. Briones, L. Shune, N. Boissel, A. Bondanza, D. Lu, X. Zhu, B. Engels, J.L. Brogdon, J. Mataraza, J. Davis, A.L. Marchal, L. Mariconti, M. Moschetta, L.M.-d. Parseval, P. Barba, and M. Dickinson, A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge TM platform, for the Treatment of Patients (Pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2021. 138(Supplement 1): p. 740-740. ORAL.

22. Zurko, J.C., N. Epperla, I. Nizamuddin, P. Torka, K.A. David, T.A. Ollila, B.T. Hess, J.B. Cohen, R. Ferdman, J. Liu, S.M. Chowdhury, K. O'Shea, J. Romancik, R. Bhansali, E. Harris, M. Sorrell, R. Masel, L. Fitzgerald, C. Galvez, S. Ma, J.N. Winter, B. Pro, L.I. Gordon, A.V. Danilov, D.M. Stephens, N.N. Shah, G. Shouse, V.P. Kenkre, S.K. Barta, and R. Karmali, Outcomes and Treatment Patterns in Patients with Aggressive B-Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy. Blood, 2021. 138(Supplement 1): p. 884-884. ORAL.

23. Shah, N.N., J.C. Zurko, D. Schneider, A. Szabo, S. Yim, M. Hamadani, T.S. Fenske, B.D. Johnson, and P. Hari, Phase 1/2 Trial of Bispecific LV20.19 CAR T-Cells for Relapsed, Refractory B-Cell Non-Hodgkin Lymphoma. Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy, 2022. 28(3): p. S10-S11. ORAL.

24. Shah, N.N., R.T. Maziarz, C.A. Jacobson, M. Ghosh, I. Isufi, M.L. Ulrickson, M.-A. Perales, M. Lunning, D.N.M. Hardy, A. Wijatyk, M. Ancukiewicz, M.M. Nallewar, K.C. Coleman, B. Prudner, E. Eromosele, R. Kaleta, and D.B. Miklos, Interim Analysis of a Phase II Study of Administered Fresh Bispecific Anti-CD20/Anti-CD19 CAR T-Cell Therapy: Zamtocabtagene Autoleucel (zamto-cel) for Relapsed/ Refractory (R/R) DLBCL (DALY II USA NCT04792489). Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy, 2023. 29(2): p. S13-S14. ORAL.

25. Shah, N.N., F. Furqan, A. Szabo, J. Neumann, P. Hari, D. Schneider, B.D. Johnson, M. Hamadani, and T.S. Fenske, Results from a Phase 1/2 Study of Tandem, Bispecific Anti-CD20/Anti-CD19 (LV20.19) CAR T-Cells for Mantle Cell Lymphoma. Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy, 2023. 29(2): p. S33-S34. ORAL.

26. Shah, N.N., F. Furqan, A. Szabo, T. Kearl, A. Zamora, J. Neumann, P.N. Hari, D. Schneider, W. Longo, P. Hematti, B.D. Johnson, M. Hamadani, and T.S. Fenske, Adaptive Manufacturing of LV20.19 CAR T-Cells for Relapsed, Refractory Mantle Cell Lymphoma. Blood, 2023. 142(Supplement 1): p. 1024-1024. ORAL.

27. Shah, N.N., E.L. Atallah, S. Abedin, G.S.G. Murthy, L. Runaas, L.C. Michaelis, W. Longo, F. Furqan, D. Bucklan, A. Szabo, T. Kearl, D. Schneider, K. Palen, B.D. Johnson, P. Hematti, T.S. Fenske, and M. Hamadani, Phase 1 Trial of LV20.19 CAR T-Cells for Relapsed, Refractory CLL and Richter's Transformation. Transplantation and Cellular Therapy, 2024. 30(2, Supplement): p. S35-S36. ORAL.

28. Shah, N.N., C. Kucharczuk, N. Mitra, R. Hirsh, J. Svoboda, D. Porter, A.W. Loren, N.V. Frey, and M.M. Schapira, Provider Based Outcomes on an Allogeneic Transplant Service. Blood, 2014. 124(21): p. 2643-2643. POSTER.

29. Nagle, S.J., N.N. Shah, A. Ogdie, D.J. Landsburg, A. Mato, S.D. Nasta, S.J. Schuster, and J. Svoboda, The Impact of Autoimmune Disease on Clinical Outcomes of Patients with DLBCL and FL. Blood, 2014. 124(21): p. 2974-2974. POSTER.

30. Huntington, S.F., N.N. Shah, A. Epstein, and A.W. Loren, The Impact of Marital and Socioeconomic Status on Outcomes of Patients with Acute Promyelocytic Leukemia. Blood, 2014. 124(21): p. 1282-1282. POSTER.

31. Hsu, J., A.J. Kumar, M.P. Carroll, N.V. Frey, N.N. Shah, Z. Jianhua, E.O. Hexner, A.W. Loren, J.K. Mangan, A.E. Perl, D. Porter, J. Morrissette, and S.M. Luger, ASXL1 Mutations in AML: Molecular Biomarker for Secondary AML? Blood, 2014. 124(21): p. 2343-2343. POSTER.

32. Schuster, S.J., J. Svoboda, S. Nasta, D.L. Porter, A. Mato, G.D. Shah, D.J. Landsburg, E.A. Chong, S.F. Lacey, J.J. Melenhorst, A. Chew, J. Hasskarl, N.N. Shah, M.A. Wasik, K. Marcucci, Z. Zheng, B. Levine, and C.H. June, Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas. Journal of Clinical Oncology, 2015. 33(15_suppl): p. 8516-8516. POSTER.

33. Shah, N.N., D.A. Torigian, M. Farwell, W.T. Hwang, N.V. Frey, S. Nasta, D.J. Landsburg, A.R. Mato, C.H. June, S.J. Schuster, D.L. Porter, and J. Svoboda, Utility of FDG-PET/CT in lymphoma patients undergoing immunotherapy with autologous CTL019 T-cells. Journal of Clinical Oncology, 2015. 33(15). POSTER.

34. Shah, N., N. Mitra, J. Brikman, S. Nasta, D. Landsburg, A. Mato, D. Vogl, N. Frey, S. Schuster, and J. Svoboda, Abstract 3427: Split-dose R-CHOP: A novel approach to administer cytotoxic chemotherapy to geriatric patients with DLBCL. Cancer Research, 2015. 75(15 Supplement): p. 3427-3427. POSTER.

35. Nagle, S.J., N.N. Shah, A. Ganetsky, D.J. Landsburg, S. Dwivedy Nasta, A. Mato, S.J. Schuster, D.E. Tsai, and J. Svoboda, Long Term Outcomes of Rituximab, Temozolamide, and High-Dose Methotrexate for Lymphoma Involving the Central Nervous System. Blood, 2015. 126(23): p. 2701-2701. POSTER.

36. Svoboda, J., L.E. Strelec, S.D. Nasta, D.J. Landsburg, A.R. Mato, B. Pro, S.K. Barta, N.N. Shah, S.J. Nagle, E.A. Chong, E. Napier, S. Garrett, and S.J. Schuster, Brentuximab Vedotin in Combination with Multi-Agent Chemotherapy Is Well Tolerated and Shows Promising Activity As Frontline Treatment for Primary Mediastinal B-Cell Lymphoma. Blood, 2015. 126(23): p. 2694-2694. POSTER.

37. Strelec, L.E., E. Haley, E.J. Kim, A.H. Rook, N.N. Shah, A.R. Mato, D.J. Landsburg, S.D. Nasta, S.J. Schuster, and J. Svoboda, Unique Characteristics of Classical Hodgkin Lymphoma in Patients with Cutaneous T-Cell Lymphoma. Blood, 2015. 126(23): p. 5003-5003. POSTER.

38. Zhu, F., N.N. Shah, H. Xu, D. Schneider, R. Orentas, B. Dropulic, P. Hari, and C.A. Keever-Taylor, CAR-T Cell Production Using the Clinimacs Prodigy System. Blood, 2016. 128(22): p. 5724-5724. POSTER.

39. Voshtina, E., A. Szabo, M. Hamadani, T.S. Fenske, A. D'Souza, W. Saber, W.R. Drobyski, P. Hari, and N.N. Shah, Impact of Obesity on Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Myeloid Malignancies. Blood, 2016. 128(22): p. 4667-4667. POSTER.

40. Epperla, N., T.S. Fenske, H. Olteanu, J. Pruett, A. Goff, K. Zellner, M. Hamadani, and N.N. Shah, Outcomes of Grade 3A Follicular Lymphoma: Best Treated As Aggressive or Indolent Lymphoma? Blood, 2016. 128(22): p. 5328-5328. POSTER.

41. Shah, N., F. Zhu, H. Xu, D. Schneider, R. Orentas, B. Dropulic, P. Hari, and C. Keever-Taylor, Dual Targeted CD20/19 CAR-T Cell Production Using the Clinimacs Prodigy System. Biology of Blood and Marrow Transplantation, 2017. 23(3): p. S162. POSTER.

42. Drobyski, W., A. Szabo, P. Hari, M. Hamadani, K. Herbert, C. Keever-Taylor, A. D'Souza, M. Eapen, T.S. Fenske, M.M. Horowitz, J.D. Rizzo, W. Saber, N. Shah, B.E. Shaw, S. Yim, and M.C. Pasquini, Results of a Phase II Clinical Trial of Tocilizumab, Tacrolimus and Methotrexate (Toc/Tac/MTX) for the Prevention of Acute Graft Versus Host Disease (GVHD) and Matched Case Control Comparison to Tac/MTX after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017. 23(3): p. 1. POSTER.

43. Narayana, S., S. Chhabra, R.K. Narra, A. Szabo, M. Hamadani, M.C. Pasquini, N. Shah, and P. Hari, Allogeneic hematopoietic cell transplantation for myelofibrosis (MF) in high risk patients. Journal of Clinical Oncology, 2017. 35(15_suppl): p. 7062-7062. POSTER.

44. Pawarode, A., A. D'Souza, M.C. Pasquini, B. Johnson, T. Braun, B. Dhakal, M. Hamadani, J.M. Magenau, N.N. Shah, M.M. Riwes, B. Parkin, P. Reddy, and P. Hari, Phase 2 Study of Pembrolizumab during Lymphodepleted State after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Patients. Blood, 2017. 130(Suppl 1): p. 339-339. POSTER.

45. Chhabra, S., P. Hari, A. Visotcky, N.N. Shah, J.D. Rizzo, W. Saber, A. D'Souza, B. Dhakal, A. Anshu, R. Thompson, T.S. Fenske, B.E. Shaw, W.R. Drobyski, M.C. Pasquini, and M. Hamadani, Ixazomib for Chronic Graft-Versus-Host Disease (cGVHD) Prophylaxis in Patients Undergoing Allogeneic Transplantation (alloHCT): Preliminary Results of a Phase I/II Study. Blood, 2017. 130(Suppl 1): p. 1974-1974. POSTER.

46. Bair, S.M., L.E. Strelec, T.A. Feldman, N.N. Shah, N. Reddy, N. Khan, C. Andreadis, C.S. Ujjani, A.K. Singavi, C. Howlett, K. Vu, M. Faheem, M.R. Youngman, S. Dwivedy Nasta, D.J. Landsburg, A.R. Mato, S.J. Schuster, and J. Svoboda, Outcomes, Toxicities, and Patterns of Use of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Multicenter Retrospective Study. Blood, 2017. 130(Suppl 1): p. 4091-4091. POSTER.

47. Mato, A.R., C.S. Tam, J.N. Allan, D.M. Brander, J.M. Pagel, C.S. Ujjani, B.T. Hill, N. Lamanna, F. Lansigan, R. Jacobs, M. Shadman, A.P. Skarbnik, J.J. Pu, P.M. Barr, A.R. Sehgal, B.D. Cheson, C.S. Zent, H.H. Tuncer, S.J. Schuster, P.V. Pickens, N.N. Shah, A.M. Winter, K. Kennard, K. Isaac, C. Dorsey, A.M. Vandegrift, A.K. Singavi, A. Williams, C. Howlett, H. Weissbrot, N. Ali, S. Khajavian, A. Sitlinger, E. Tranchito, J. Rhodes, E.B. Bhavsar, N. Bailey, B. Patel, T.F. Burns, M. Yacur, M. Malhotra, S. Handunnetti, J. Svoboda, R.R. Furman, and C. Nabhan, Disease and Patient Characteristics, Patterns of Care, Toxicities, and Outcomes of Chronic Lymphocytic Leukemia (CLL) Patients Treated with Venetoclax: A Multicenter Study of 204 Patients. Blood, 2017. 130(Suppl 1): p. 4315-4315. POSTER.

48. Mato, A.R., J.N. Allan, J.M. Pagel, D.M. Brander, B.T. Hill, B.D. Cheson, R.R. Furman, N. Lamanna, C.S. Tam, R. Jacobs, F. Lansigan, P.M. Barr, M. Shadman, A.P. Skarbnik, D.F. Beach, J.J. Pu, A.R. Sehgal, A.M. Winter, C.S. Zent, H.H. Tuncer, A.K. Singavi, S.J. Schuster, P.V. Pickens, N.N. Shah, A. Williams, C. Howlett, H. Weissbrot, N. Ali, B. Patel, K. Isaac, J. Rhodes, M.E. Hughes, S. Khajavian, E.T. Chatburn, A. Sitlinger, E. Tranchito, E.B. Bhavsar, N. Bailey, T.F. Burns, M. Yacur, M. Malhotra, S. Handunnetti, K. Kennard, C. Nabhan, and C.S. Ujjani, Front-Line Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) in the Real World: Responses, Toxicity, Outcomes and Subsequent Therapies. Blood, 2017. 130(Suppl 1): p. 3011-3011. POSTER.

49. Floisand Y., Lazarevic, V., Maertens, J., Mattsson, J., Shah, N., Zachee, P., Taylor, A., Akbari, M., Quadri, S., Chen, Y. Safety and Efficacy of Vedolizumab in Patients with Steroid Refractory Acute Gastrointestinal Graft-versus-Host Disease: A Retrospective Chart Review. European Hematological Association 23rd Annual Congress. June 15, 2018. POSTER.

50. Taylor, A., Johnson, B., Kim, G., Drahos, J., Yang, J., Akbari, M., Shah, N. Acute Intestinal Graft-Versus-Host Disease Among Patients Undergoing Allogenic Stem Cell Transplant for Hematological Malignancy in the United States: A Retrospective Claims Database Analysis. European Hematological Association 23rd Annual Congress. June 6, 2018. POSTER.

51. Badar, T., N. Epperla, A. Szabo, S. Borson, J. Vaughn, G. George, N.N. Shah, A.F. Cashen, M. Hamadani, and T.S. Fenske, Trends in Post-Relapse Survival in Classical Hodgkin Lymphoma Patients after Experiencing Therapy Failure Following Autologous Hematopoietic Cell Transplantation. Blood, 2018. 132(Suppl 1): p. 2918-2918. POSTER.

52. Dhakal, B., A. D'Souza, M. Hamadani, C.E. Arce-Lara, K. Schroeder, S. Chhabra, N.N. Shah, K. Gauger, T. Keaton, M.C. Pasquini, and P. Hari, Phase I/II Trial of Bendamustine, Ixazomib and Dexamethasone (BID) in Patients (pts.) with Relapsed/Refractory Multiple Myeloma (RRMM). Blood, 2018. 132(Suppl 1): p. 1998-1998. POSTER.

53. Guru Murthy, G.S., A. Szabo, M. Hamadani, T.S. Fenske, and N.N. Shah, Improvements in Clinical Outcomes of Advanced Stage Classical Hodgkin Lymphoma in the United States from 2000-2014: Analysis of Surveillance Epidemiology and End Results Database. Blood, 2018. 132(Suppl 1): p. 2939-2939. POSTER.

54. Mato, A.R., L.E. Roeker, T.A. Eyre, C. Nabhan, N. Lamanna, B.T. Hill, D.M. Brander, P. Barr, F. Lansigan, B. Cheson, A.K. Singavi, M. Yazdy, N.N. Shah, J.N. Allan, E.B. Bhavsar, J. Rhodes, K. Kennard, S.J. Schuster, A.M. Williams, A.P. Skarbnik, A. Goy, C.C. Coombs, H.H. Tuncer, C.S. Ujjani, R. Jacobs, A.M. Winter, J.M. Pagel, N. Bailey, A. Schuh, M. Shadman, A. Sitlinger, H. Weissbrot, S. Muralikrishnan, A.A. Kirkwood, and C.P. Fox, Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients. Blood, 2018. 132(Suppl 1): p. 3142-3142. POSTER.

55. Shah, N.N., F. Zhu, C. Taylor, D. Schneider, W. Krueger, A. Worden, S. Yim, T.S. Fenske, M. Hamadani, B. Johnson, B. Dropulic, R. Orentas, and P. Hari, A Phase 1 Study with Point-of-Care Manufacturing of Dual Targeted, Tandem Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CAR-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma. Blood, 2018. 132(Suppl 1): p. 4193-4193. POSTER.

56. Zhu, F., N.N. Shah, D. Schneider, H. Xu, K. Chaney, L. Luib, C.A. Keever-Taylor, B. Dropulic, R. Orentas, P. Hari, and B. Johnson, Point-of-Care Manufacturing of CD20.19 Bi-Specific Chimeric Antigen Receptor T (CAR-T) Cells in a Standard Academic Cell Processing Facility for a Phase I Clinical Trial in Relapsed, Refractory NHL. Blood, 2018. 132(Suppl 1): p. 4553-4553. POSTER.

57. Dhakal, B., S. Giri, A. Levin, R. Lisa, T.S. Fenske, S. Chhabra, N.N. Shah, A. Szabo, A. D'Souza, M.C. Pasquini, P. Hari, and M. Hamadani, Incidence and Predictors of 30-Day Readmissions Following Autologous Hematopoietic Cell Transplantation (auto-HCT) in the US. Blood, 2018. 132(Suppl 1): p. 3544-3544. POSTER.

58. Dhakal, B., S. Giri, A. Levin, R. Lisa, T.S. Fenske, S. Chhabra, N.N. Shah, A. Szabo, A. D'Souza, M.C. Pasquini, P. Hari, and M. Hamadani, Association between Transplant Volumes and 30-Day Readmissions Following Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in the US. Blood, 2018. 132(Suppl 1): p. 617-617. POSTER.

59. Chhabra, S., P. Hari, A. Visotcky, F. Zhu, K. Cantrall, S. Abedin, B. Dhakal, A. D'Souza, W.R. Drobyski, T.S. Fenske, J. Jerkins, J.D. Rizzo, L. Runaas, W. Saber, N.N. Shah, B.E. Shaw, M.C. Pasquini, and M. Hamadani, A Phase I/2 Study of Ixazomib for Chronic Graft-Versus-Host Disease (cGVHD) Prophylaxis after Allogeneic Transplantation (alloHCT). Biology of Blood and Marrow Transplantation, 2019. 25(3): p. S224-S225. POSTER.

60. Abid, M.B., A. Szabo, M. Hamadani, M.B. Graham, P. Hari, J. Jerkins, N.N. Shah, S. Abedin, L. Runaas, W.L. Longo, and S. Chhabra, Severity of Cytokine Release Syndrome As a Predictor of Infections after T-Cell Replete Haploidentical Hematopoietic Cell Transplantation (haploHCT). Biology of Blood and Marrow Transplantation, 2019. 25(3): p. S368. POSTER.

61. Badar, T., M.A. Khan, A. Szabo, B. Dhakal, S. Chhabra, T.S. Fenske, N.N. Shah, P. Hari, and A. D'Souza, Rates of Engraftment Syndrome after Autologous Stem Cell Transplantation in Patients with Immunoglobulin Light Chain Amyloidosis. Biology of Blood and Marrow Transplantation, 2019. 25(3): p. S410-S411. POSTER.

62. Shah NN, Krishnan AY, Shah ND, et al. Abstract CT104: A Phase I open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-001, an anti-CD74 antibody drug conjugate, in patients with advanced B-cell malignancies. Cancer research. 2019;79(13 Supplement). POSTER.

63. Shah, N.N., F. Zhu, D. Schneider, W. Krueger, A. Worden, W.L. Longo, M. Hamadani, T.S. Fenske, B. Dropulic, R.J. Orentas, P. Hari, and B. Johnson, Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma. Blood, 2019. 134(Supplement_1): p. 4465-4465. POSTER.

64. Luo, T., T.S. Fenske, M. Hamadani, P. Hari, and N.N. Shah, Allogeneic Transplant Outcomes for T-Cell Lymphomas: A Single Center Analysis. Blood, 2020. 136(Supplement 1): p. 20-21. POSTER.

65. Xu, H., K. Chaney, B. Johnson, T.S. Fenske, M. Hamadani, B. Dropulic, D. Schneider, P. Hari, and N.N. Shah, Single-Cell Cytokine Analysis of LV20.19 Bispecific CAR T-Cell Products from a Phase I Clinical Trial. Blood, 2020. 136(Supplement 1): p. 22-22. POSTER.

66. Shah, N.N., A.H. Mattour, L.L. Popplewell, C. Andreadis, J.M. Melear, A.I. Spira, J. Shulman, S. Manda, J.M. Burke, S. Chhabra, J.P. Sharman, A. Krishnan, N. Shah, C. DiLea, J. Kuriakose, C.J. Berman, S.L. Matheny, J.P. Leonard, and A. Molina, Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma. Blood, 2020. 136(Supplement 1): p. 29-30. POSTER.

67. Palen, K., P. Hari, N.N. Shah, and B. Johnson, Successful Manufacturing of CAR T-Cells with Small Volume Peripheral Blood from Healthy Donors Using the Clinimacs Prodigy Device. Blood, 2020. 136(Supplement 1): p. 27-28. POSTER.

68. Knight, J.M., I. Arapi, A. Szabo, S. Yim, G. Sauber, C. Hillard, P. Hari, and N.N. Shah, Quality of Life, Tryptophan Metabolites, and Neurotoxicity Assessments of Patients with Relapsed or Refractory B Cell Malignancies Undergoing CAR 20/19 - T Cell Therapy. Blood, 2020. 136(Supplement 1): p. 42-43. POSTER.

69. Galvez, C., R. Karmali, M. Hamadani, L.I. Gordon, J.N. Winter, S. Ma, V. Nelson, B.A. Palmer, T.S. Fenske, N.N. Shah, D. Jagadeesh, A. Klein, I. Helenowski, B. Jovanovic, A.M. Petrich, A.M. Evens, and B. Pro, A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib As Frontline Therapy for Patients with MYC-Aberrant Lymphoid Malignancies: The Daciphor Regimen. Blood, 2020. 136(Supplement 1): p. 44-45. POSTER.

70. Choe, H., N.N. Shah, P. Chevallier, M.T. Rubio, M.A. Schroeder, N.M. Hardy, P.J. Stiff, C. Solano, I. Yakoub-Agha, J.A. Gutman, S.D. Rowley, M.C. Mico', E. Terruzzi, R.F. Duarte, R. Morariu-Zamfir, M. Arbushites, K. Ding, and M.-A. Perales, A Single-Arm, Open-Label Phase 1 Study of Itacitinib (ITA) with Calcineurin Inhibitor (CNI)-Based Interventions for Prophylaxis of Graft-Versus-Host Disease (GVHD; GRAVITAS-119). Blood, 2020. 136(Supplement 1): p. 50-51. POSTER.

71. Bachier, C., H. Schade, B. Zoghi, A. Ramakrishnan, and N.N. Shah, A Phase II Single Arm Study of Nivolumab As Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Hodgkin Lymphoma at Risk of Relapse or Progression. Blood, 2021. 138(Supplement 1): p. 2455-2455. POSTER.

72. Cusatis, R., I. Tan, C. Piehowski, I. Akinola, E. Crawford, J. Craig, A. Thiengmany, M.J. Frank, D.B. Miklos, N.N. Shah, A. D'Souza, J.M. Knight, L. Muffly, K.E. Flynn, and S. Sidana, Worsening Financial Toxicity Among Patients Receiving Chimeric Antigen Receptor t-Cell (CAR-T) Therapy: A Mixed Methods Longitudinal Study. Blood, 2021. 138(Supplement 1): p. 567-567. POSTER.

73. Hackett, E.P., N.N. Shah, C. Hillard, E. Aughey, R. Cusatis, A. Szabo, and J.M. Knight, Associations between Socioeconomic Status and Bispecific LV20.19 CAR T-Cell Therapy Outcomes. Blood, 2021. 138(Supplement 1): p. 4084-4084. POSTER.

74. Shah, N.N., J. Zurko, T.S. Fenske, M. Hamadani, D. Schneider, H. Xu, K. Chaney, B. Dropulic, B.D. Johnson, and P. Hari, 214 - Clinical and Manufacturing Outcomes of LV20.19 CAR T-Cells Expanded in IL-2 Versus IL-7 and IL-15. Transplantation and Cellular Therapy, 2021. 27(3, Supplement): p. S194-S195. POSTER.

75. Tan, I., R. Cusatis, E. Crawford, A. Thiengmany, C. Piehowski, I. Akinola, J. Craig, S. Lahijani, M.J. Frank, N.N. Shah, A. D'Souza, D.B. Miklos, L. Muffly, K.E. Flynn, and S. Sidana, Do PROs Tell the Whole Story? Differential Outcomes Based on Patient-Reported Outcomes (PROs) Versus Performance-Based Metrics (PBM) on Cognition for Patients Receiving Chimeric Antigen Receptor (CAR)-T Cell Therapy. Blood, 2021. 138(Supplement 1): p. 3043-3043. POSTER.

76. Zurko, J., H. Xu, K. Chaney, T.S. Fenske, M. Hamadani, D. Schneider, B. Dropulic, P. Hari, B.D. Johnson, and N.N. Shah, 205 - Single Cell Cytokine Analysis of LV20.19 CAR T-Cells Expanded in IL-2 Versus IL-7 and IL-15. Transplantation and Cellular Therapy, 2021. 27(3, Supplement): p. S187-S189. POSTER.

77. Zurko, J.C., K. Chaney, H. Xu, D. Schneider, P. Hari, B. Johnson, and N.N. Shah, Manufacturing Bispecific LV20.19 CAR T-Cells with IL-7 &amp; IL-15 for a Shorter Duration Improves CAR T-Cell Immunophenotype While Maintaining Target Cell Dose. Blood, 2021. 138(Supplement 1): p. 3883-3883. POSTER.

78. Zurko, J.C., H. Xu, K. Chaney, T.S. Fenske, M. Hamadani, D. Schneider, P. Hari, B. Johnson, and N.N. Shah, Bispecific LV20.19 CAR T-Cells Expanded in IL-7 and IL-15 Have Greater Polyfunctionality and Polyfunctional Strength Than CAR T-Cells Expanded in IL-2. Blood, 2021. 138(Supplement 1): p. 1728-1728. POSTER.

79. Abid, M.B., M. Hamadani, T.S. Fenske, B.D. Johnson, A. Szabo, P. Hari, and N.N. Shah, Adaptive Lymphodepletion Impacts Immune Recovery and Infectious Complications Among CAR-T Therapy Recipients. Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy, 2022. 28(3): p. S187. POSTER.

80. Thompson, M.C., C.C. Coombs, L.E. Roeker, J.L. Jensen, N.N. Shah, T. Luo, K. Patel, N. Bailey, B. Fakhri, T.A. Eyre, P. Ghione, J.M. Rhodes, A.D. Zelenetz, J. Taylor, M.L. Palomba, K. Meyer, D. Rao, Y. Fox, J.H. Aronson, S. Court, O. Abdel-Wahab, and A.R. Mato, Outcomes of Therapies and Resistance Mutations Following Non-Covalent Bruton's Tyrosine Kinase Inhibitor Treatment for Patients with Chronic Lymphocytic Leukemia and Richter Transformation. Blood, 2022. 140(Supplement 1): p. 9885-9888. POSTER.

81. Furqan, F., E. Aschenbrenner, J. Talano, A. Moskop, W. Longo, B.D. Johnson, T.S. Fenske, M. Hamadani, and N.N. Shah, Clinical Characteristics and Patient Outcomes with HLH-like Toxicities after CD19 Based CAR T-Cell Therapy. Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy, 2023. 29(2): p. S131-S132. POSTER.

82. Furqan, F., B.D. Johnson, M. Hamadani, T.S. Fenske, and N.N. Shah, Bispecific Anti-CD20/Anti-CD19 (LV20.19) CAR T-Cells for Richter’s Transformation. Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy, 2023. 29(2): p. S377-S378. POSTER.

83. Shah, N.N., W. Jurczak, P.L. Zinzani, T.A. Eyre, C. Cheah, C.S. Ujjani, K. Izutsu, S. Ma, I.W. Flinn, A.J. Alencar, D.J. Lewis, K. Patel, K.J. Maddocks, Y. Wang, T. Munir, A.D. Zelenetz, M. Balbas, D.E. Tsai, C. Wang, and M. Wang, Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment. Journal of Clinical Oncology, 2023. 41(16_suppl): p. 7514-7514. POSTER.

84. Shah, N.N., A. Szabo, S. Rajguru, S. Devata, M. Howard, D. Pereira, M. Endres, W.L. Longo, M. Hamadani, T.S. Fenske, and C.D. Fletcher, Phase II trial of split-dose R-CHOP for older patients with diffuse large B-cell lymphoma (DLBCL). Journal of Clinical Oncology, 2023. 41(16_suppl): p. 7554-7554. POSTER.

85. Shah, N.N., P.L. Zinzani, M.L. Wang, S.D. Nasta, E. Lech-Maranda, Y. Ogawa, B. Fakhri, B. Kuss, K. Miyashita, K. Patel, C.C. Coombs, S. Ma, M. Patel, M.A. Barve, B. Tessoulin, A. Stathis, W.S. Kim, D. Ennishi, D. Hashimoto, K. Kojima, A.D. Zelenetz, J.B. Cohen, J.M. Vose, K.J. Maddocks, T. Munir, F. Sun, F. Bian, D.E. Tsai, P. Abada, and C.Y. Cheah, Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed/Refractory Follicular Lymphoma: Results from the Phase 1/2 BRUIN Study. Blood, 2023. 142(Supplement 1): p. 3026-3026. POSTER.

86. Furqan, F., K. Baird, M. Kacar, A.S. Surapaneni, U. Kemmo Tsafack, A. Szabo, J. Svoboda, B.T. Hill, J.T. Romancik, and N.N. Shah, Multicenter Study to Assess the Outcomes and Prognosis of Richter's Transformation in the Era of Novel Agents and Cell Therapy. Blood, 2023. 142(Supplement 1): p. 4486-4486. POSTER.

87. Furqan, F., V. Bhatlapenumarthi, F. Farrukh, T.S. Fenske, W. Longo, N.N. Shah, A. D'Souza, M.C. Pasquini, G.S.G. Murthy, L. Runaas, S. Abedin, M. Mohan, B. Dhakal, and M. Hamadani, Outpatient Administration of Commercial antiCD19 and Antibcma Chimeric Antigen Receptor-Modified T-Cell (CAR-T) Therapies Using a Strategy of No Remote Monitoring and Early Cytokine Release Syndrome (CRS) Intervention. Transplantation and Cellular Therapy, 2024. 30(2, Supplement): p. S211. POSTER.

88. Furqan, F., A. Szabo, T. Kearl, A.E. Zamora, M. Dwinell, J. Neumann, P. Hari, D. Schneider, P. Hematti, B.D. Johnson, M. Hamadani, and N.N. Shah, Fresh Versus Cryopreserved LV20.19 CAR T-Cell Therapy for Relapsed, Refractory DLBCL and Follicular Lymphoma. Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy, 2024. 30(2): p. S211-S212. POSTER.

89. Shah, N.N., T. Siddiqi, D.G. Maloney, S.S. Kenderian, D.M. Brander, K. Dorritie, J. Soumerai, P.A. Riedell, R. Nath, B. Fakhri, D.M. Stephens, S. Ma, T. Feldman, S.R. Solomon, S.J. Schuster, S.K. Perna, S.A. Tuazon, S.-S. Ou, N. Rane, and W.G. Wierda, Lisocabtagene Maraleucel (liso-cel) in Patients (Pt) With R/R CLL/SLL: 24-Mo Median Follow-up of TRANSCEND CLL 004. Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy, 2024. 30(2): p. S353-S354. POSTER.

90. Furqan, F., K. Palen, B.D. Johnson, T. Kearl, P. Hematti, W. Longo, M. Hamadani, T. Fenske, and N.N. Shah, Combination of pirtobrutinib and lentiviral transduced bispecific anti-CD20/CD19 (LV20.19) CAR T-cell therapy to improve outcomes in patients with relapsed/refractory lymphoma. Journal of Clinical Oncology, 2024. 42(suppl 16; abstr 7043). POSTER.